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LITERATURE REVIEW
	 1	
INTRODUCTION 
Thrombocytopenia results from one or more of three processes: (1) decreased bone 
marrow production, (2) sequestration, usually in an enlarged spleen, and/or (3) 
increased platelet destruction. In evaluating the mechanism of thrombocytopenia, it is 
necessary to know which pathogenic mechanism is the more dominant one, decreased 
production or increased destruction, since treatment is vastly different for the two 
entities. For this purpose, bone marrow aspiration is often used. A bone marrow 
examination provides information about the degree of thrombopoiesis by judging the 
adequacy of megakaryocytes but it is subject to sampling errors, delays and subjective 
interpretation. 
The concept of ‘young’ platelets or reticulated platelets has been around for over 40 
years and for several years after its discovery in 1969, has been a topic of intense 
research, especially as evidence of it being a good indicator of thrombopoiesis mounted. 
Up until the late 1990’s, the only way to quantify them was by fluorescence flow 
cytometry, which had a large repertoire of drawbacks. With the advent of automated 
hematology analysers, automated methods of reticulated platelet estimation also came 
into being, in the forefront of which is the Immature Platelet Fraction or IPF. In the 
recent past, there has been a lot of research done on the utility of IPF in the differential 
diagnosis of thrombocytopenia and it is proving to be an inexpensive, non-invasive and 
reliable alternative to a bone marrow examination. It is also gaining importance as a 
marker of platelet recovery in patients with thrombocytopenia due to chemotherapy or 
post hematopoietic stem cell transplant. This knowledge is being used to curtail 
unnecessary prophylactic platelet transfusions in these patients. 
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In addition to IPF, hematology analysers also provide an array of platelet parameters 
like Mean Platelet Volume (MPV), Plateletcrit (PCT), Platelet Large Cell Ratio (P-
LCR) and Platelet Distribution Width (PDW), most of which are not yet approved for 
routine clinical use as there is limited data available on them. 
Most studies relating to IPF have been carried out in the West and in Japan. There is no 
study from India that has researched the utility of Immature Platelet Fraction in the 
diagnosis of thrombocytopenia or its predictive value in platelet recovery in patients 
with a recovering marrow. The study of platelet morphology under the light microscope 
in cases of thrombocytopenia has also been a neglected area in the recent years and 
there have been no studies that have looked at platelet morphology in relation these 
newer platelet parameters. 
This study will be the first of its kind from India to look at the utility of all the novel 
platelet parameters in conjunction with platelet morphology on smear in the diagnosis 
of thrombocytopenia and also the first from India to study patterns of IPF in patients 
with a recovering marrow. 
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PLATELETS – PRODUCTION AND MORPHOLOGY 
Platelets were first discovered in 1865 by German anatomist, Max Schultze and further 
described in 1882 by Italian pathologist Giulio Bizzozero (1). Platelets play a major role 
in inflammation mediated disease processes, immunity and angiogenesis apart from its 
primary role in coagulation (2). 
Platelets are small enucleate cytoplasmic fragments, which are formed in the bone 
marrow from megakaryocytes. They are produced in response to thrombopoietin, a 
glycoprotein that is produced in the liver, kidney and bone marrow. The receptor for 
thrombopoietin, c-Mpl, which is a proto-oncogene, is expressed on megakaryocytes and 
their precursors, platelets, endothelial cells and other hematopoietic stem cells and the 
levels of thrombopoietin are usually inversely proportional to the platelet count (3). 
Megakaryocytes mature by a process called endomitosis where in the nuclear material 
undergo continuous replication without accompanying cytoplasmic division. This leads 
to the formation of a cell with a large multilobate, polyploid nucleus with a DNA 
content ranging from 2n – 128n. As the megakaryocytes mature, they also develop a 
complex assembly of tubules and cisternae across its cytoplasm, which is in 
communication with the plasma membrane. This is called the Invaginated Membrane 
System (IMS). A mature megakaryocyte then extends pseudopod like branching 
projections into the bone marrow sinusoids called proplatelets. Proplatelets are 
composed of a long tapering tubule called the proplatelet shaft with platelet-sized 
swellings along it. These proplatelets serve as channels along which the platelet 
granules and organelles packaged in the megakaryocyte cytoplasm are transported  
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into platelets. The entire megakaryocyte cytoplasm is converted into proplatelets and 
the nucleus is finally extruded and degraded. 
Individual platelets are pinched off from the tips of these proplatelets due to the shear 
force created as blood flows through the sinusoids (2,4). An intermediate stage of 
platelet development called a preplatelet has also been recently described. These are 
discoid, anucleate megakaryocyte cytoplasmic fragments that are 2 to 10 µm in 
diameter. The number of preplatelets has been found to increase following recovery 
after a thrombocytopenic insult.  As a result, they are also being equated to large young 
platelets in circulation. Preplatelets can mature to form a proplatelet from which two 
platelets are finally released by fission (5). Around 1 x 1011 platelets are released per 
day into the circulation and each platelet has a life span of 8-10 days (3). The normal 
platelet count ranges from 150000/µL to 450000/µL (6). 
On a peripheral blood smear stained with a Romanowsky dye, platelets appear as small 
discoid structures, 1.5 - 3 µm in diameter with a weakly basophilic cytoplasm and 
numerous azurophilic granules, which are dispersed uniformly or concentrated in the 
center of the cell as a granulomere. These correspond to the platelet alpha granules. 
Platelets greater than 4 µm in diameter are called large platelets and those that have a 
diameter similar to that of an erythrocyte is called a giant platelet (7). Larger platelets 
are thought to be the more recently released platelets and is an indicator of 
thrombopoiesis (8). A study by Zeigler et al. reported that large platelets were seen in 
individuals with thrombocytopenia due to ITP whereas platelet size was normal in 
patients with thrombocytopenia due to bone marrow aplasia, hypersplenism or ITP 
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with a normal platelet count (9). Giant platelets are seen in inherited 
macrothrombocytopenic disorders like Bernard Soulier syndrome, MYH9 related 
disorders, Mediterranean macrothrombocytopenia etc. (10). Thus, the study of platelet 
morphology can give us a good clue towards the etiology of thrombocytopenia. 
 
ETIOLOGIES OF THROMBOCYTOPENIA 
Thrombocytopenia is defined as a platelet count below the 2.5th lower percentile of the 
normal platelet count distribution and this value has traditionally been taken as 
150000/µL (11). An international working group in 2008 came up with the proposal 
that a platelet count of less than 100000/µL should be used to diagnose pathologically 
significant thrombocytopenia as counts between 100000/µL and 150000/µL could be 
seen in apparently healthy individuals (12). 
There are 4 main pathophysiological mechanisms of thrombocytopenia (13): 
1. Decreased production from the bone marrow 
2. Increased peripheral destruction 
3. Increased sequestration in spleen 
4. Dilution 
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The most important conditions that come under each group are listed out below 
(14)(15): 
PERIPHERAL DESTRUCTION 
1. Immune causes 
- Immune thrombocytopenic purpura 
- Post transfusion purpura 
- Neonatal alloimmune thrombocytopenia 
 
2. Non-Immune causes 
- Hypersplenism due to any cause 
- Disseminated Intravascular coagulation (DIC) 
- Thrombotic thrombocytopenic purpura (TTP) 
- Heparin induced thrombocytopenia (HIT) 
 
DECREASED PRODUCTION 
- Drug induced ex: Thiazide diuretics, ethanol, cytotoxic chemotherapy 
- Viral infections - Hepatitis C virus, Human immunodeficiency virus,     
          Cytomegalovirus 
- Bacterial infections 
- Myelodysplastic syndrome 
- Vitamin B12 and Folic acid deficiency 
- Aplastic anaemia 
- Hematological malignancies (leukemia, lymphomas, myeloma) 
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- Metastasis from solid tumors to the bone marrow 
 
DILUTIONAL 
- Massive transfusion with non-platelet blood products 
- Gestational thrombocytopenia 
 
PSEUDO-THROMBOCYTOPENIA 
- Large platelets (Due to mis-counting of platelets as red blood cells in hematology 
analysers) 
-  Anticoagulant induced (Ethylenediamenetetraacetic acid [EDTA] induced platelet 
aggregation). 
Thrombocytopenias can also be inherited, and in this case they are classified based on 
their mode of inheritance or platelet size. Based on platelet size, the inherited 
thrombocytopenias are listed out below (10,14): 
SMALL PLATELETS 
- Wiskott Aldrich syndrome 
- X – Linked thrombocytopenia 
NORMAL PLATELET SIZE 
- Congenital amegakaryocytic thrombocytopenia 
- Thrombocytopenia with absent radius syndrome 
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LARGE PLATELETS (MACROTHROMBOCYTOPENIA) 
- Bernard Soulier Syndrome 
- Grey Platelet Syndrome 
- Mediterranean macrothrombocytopenia 
- MYH-9 related disorders (Ex: May-Heggelin anomaly, Sebastian syndrome, 
Fetchner syndrome) 
- Paris – Trousseau syndrome 
 
METHODS FOR COUNTING PLATELETS 
The path towards developing an accurate platelet count has been one that has been 
riddled with many problems, owing mainly to the tiny size of these blood cells and 
therefore possible interference by the larger red blood cells or the difficulty in 
separating them out from background noise during the process of gating in automated 
hematology analysers. Currently, there are several approved methods by which a 
platelet count can be obtained. Broadly, these can be divided into manual methods and 
automated methods. The manual methods used in platelet counting can be either direct 
or indirect. Direct method involves phase contrast microscopy using the Neubaeur 
counting chamber method. Indirect method involves estimation of platelets on a stained 
peripheral smear. The automated methods that are performed in automated hematology 
analysers employ the principles of electrical impedance, optical light scatter and 
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fluorescence and flow cytometry using flourochrome labeled antibodies to specific 
platelet antigens. For all these methods, freshly collected, anticoagulated venous blood 
is the preferred sample. Blood samples obtained by capillary prick method usually have 
a lower platelet count due to platelet aggregation at the site of prick (6). 
Phase contrast microscopy was introduced in 1953 by Brecher, Schneiderman and 
Cronkite(16) and in 1988, was accepted as the international reference method for the 
estimation of platelets by the International Council for Standardization in Hematology 
(ICSH). In this method, whole blood is diluted in ammonium oxalate solution whereby 
the red blood cells are lysed leaving the platelets and white blood cells intact. The 
diluted blood is then charged onto a Neubauer counting chamber (hemocytometer) and 
platelets are counted under a phase contrast microscope (17). This method has several 
drawbacks in that it is time consuming, prone to pre-analytical errors, subjective and 
has a high inter-observer variability with a coefficient of variation of 10%-25% (18). 
The advantage of this method is that it is cost effective and universally available. 
The other manual method for estimation of platelets is an indirect method wherein the 
number of platelets are estimated by examining a peripheral smear stained with a 
Romanowsky dye. A field in which red blood cells are just overlapping is chosen and a 
count is performed here. One platelet per oil immersion field (1000x magnification) is 
considered equivalent to 15000 platelets/µL of blood (19)(20). The advantage of this 
method is that platelet morphology as well as presence of platelet aggregates which 
would lead to spuriously low platelet counts could be studied simultaneously. 
Automated methods of blood cell counting came into widespread existence after the 
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discovery of the Coulter principle in 1953 by Wallace Coulter (21). The coulter 
principle capitalizes on the fact that blood cells are poor conductors of electricity. When 
cells suspended in a conducting medium are passed through an aperture across which a 
direct current is applied, they provide a resistance to the flow of current, which is called 
impedance. This resistance is picked up as a voltage peak by an ohmmeter. The 
amplitude of the voltage peak is proportional to the size of the cell and the number of 
voltage peaks corresponds to the number of cells that have passed through the aperture. 
The series of voltage peaks obtained is converted into a histogram with number of 
events on y-axis and volume on x-axis and the area under the curve of the histogram is 
taken as the platelet count. This method therefore is able to count as well as size the 
blood cells. Platelet counting using the Coulter principle started by the early 1970s and 
most automated hematology analysers now provide the impedance platelet count as 
their default platelet count. Due to the larger number of cells analysed and objectivity 
in analysis, there was a drastic reduction in the coefficient of variation for platelet 
counts. Analysers use different volume cut offs to distinguish between platelets and red 
blood cells as both are counted through the same channel. Here in lies the greatest 
disadvantage of this method as abnormalities in red cell or platelet size may lead to 
either being wrongly categorized. For example, microcytic or fragmented red cells may 
be wrongly categorized as platelets leading to a falsely high platelet count or giant 
platelets and platelet clumps may be mistaken for red cells leading to a spuriously low 
platelet count. In these situations, the analyser will generate an instrument flag and an 
abnormal platelet histogram and to get the true platelet count, a peripheral smear review 
becomes necessary (22). An advantage of this method is its low cost as compared to 
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other automated techniques and its high accuracy when the platelet size and red cell 
morphology is normal. 
Another method for platelet counting is the optical method, which can be carried out 
with or without the addition of a fluorescent dye. This is also an automated method 
employed in hematology analysers. In this method, a pre-determined amount of blood 
is aspirated by the analyser and mixed with diluting fluid. A fluorescent dye that binds 
to nucleic acids may be added to this suspension depending on the type of analyser 
being used and this is then passed through a flow cell after hydrodynamic focusing. The 
stream of cells is made to flow across a light source, usually a semi-conductor diode 
laser or a helium-neon laser. As the laser light hits a blood cell, it is scattered in various 
directions. In general, forward angle light scatter gives information about size of the 
cell and side scatter gives information about the cell contents. The angles used in 
analysis vary from instrument to instrument. If a fluorescent dye is also added, then the 
dyes bind to the nucleic acids, mostly to ribonucleic acid which is seen in abundance in 
the mitochondria and ribosomes of blood cells. As the laser light hits the flourochrome, 
it emits fluorescence and different blood cells can be differentiated based on the 
intensity of side fluorescent light. These parameters are plotted on a graph where each 
event is depicted by a colored dot. In this way, platelets can be counted and 
differentiated from other blood cells based on difference in scattered light and 
fluorescence intensity (17). This method over comes the limitation of the impedance 
method of misclassifying red cells as platelets and vice versa as the fluorescent dye will 
not bind to red cells since they lack nucleic acids and hence red cells will not emit any 
fluorescence. The optical fluorescence count has also been found to be more accurate 
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than impedance counts in thrombocytopenic samples since it correlates better with the 
international reference method (23). On the other hand, for patients on chemotherapy 
for hematological malignancies, the impedance count has been found to be more 
accurate than the fluorescent count. This has been attributed to the presence of nucleic 
acid rich cytoplasmic fragments of blasts that take up the fluorescent dye and lead to 
spuriously high platelet counts (24)(25). 
The most recent advancement in platelet counting is the introduction of immunological 
platelet counting. In 2001, the International Council for Standardization in Laboratory 
Hematology expert panel on cytometry and the International Society of Laboratory 
Hematology Task Force on Platelet Counting accepted this method as the new reference 
method for platelet counting. In this method, pre-diluted EDTA anticoagulated blood is 
mixed with platelet specific monoclonal antibodies, CD61 and CD41 and a 1:1000 
dilution is made which is used for analysis. The antibodies are conjugated to fluorescein 
isothiocyanate (a flourochrome) and are targeted against 2 distinct epitopes on the 
glycoprotein IIb/IIIa complex of platelets. Initially a red blood cell count is obtained 
using a semi-automated impedance counter. The platelet count is obtained by a flow 
cytometer where the antibody bound platelets emit fluorescence as they pass across a 
beam of laser light. At least 1000 platelet events are analysed and the platelet count is 
obtained by looking at the ratio of RBCs to platelets. All hematology analysers are now 
calibrated using this reference method (18). The only limitation of this method is its 
lack of universal availability and high running costs. 
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PLATELET COUNTING PRINCIPLES OF ANALYSERS USED IN THIS STUDY 
Three hematology analysers were used in this study and each differ slightly in the 
methods of platelet counting that they employ. The analytical principles used in each 
are as follows: 
 
1. Beckman Coulter UniCel® DXH™ 800 (Miami, FL, USA): In this analyser, 
platelets are counted by impedance technology. 165 µL of blood is aspirated, 
diluted with an isotonic diluent and divided into two aliquots, one of which 
passes into the red blood cell / platelet chamber which is a common chamber 
for counting red cells and platelets. In here it passes through three apertures 
across which an electric current is applied and according to Coulter principle, 
voltage pulses are generated which are collected and analysed by a detector. 
Red blood cells (RBCs) and platelets are distinguished based on size, with 
particles between 2 to 20 fL being counted as platelets and particles more than 
36 fL being counted as RBCs. Platelet pulses are analysed through 64 size 
distribution channels and a platelet volume histogram is obtained. Using the 
statistical least squares principles, this raw histogram is fitted to a lognormal 
curve and extrapolated from 0 to 70 fL to account for background noise and 
large platelets. The final platelet count is derived from the area under the curve. 
If the machine is unable to fit a curve, then system flags are generated which 
alerts the user to the presence of an abnormal platelet distribution due to either 
large platelets or platelet clumps (22,26). 
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2. Sysmex® XN-9000 (Sysmex, Kobe, Japan): This analyser provides three 
different platelet counts; Impedance based platelet count (PLT-I) and optical 
scatter and fluorescence based platelet counts (PLT-O and PLT-F). PLT-I is 
measured through a common RBC/PLT chamber using the Coulter principle. 
Instead of fixed thresholds, floating thresholds are used and the machine 
according to sample characteristics determines the lower and upper 
discriminators for a cell population. For platelets, the lower thresholds are 
between 2 – 6 fL and upper thresholds are between 12 – 30 fL. In this way, if 
large platelets are present, it will be included in the count, as the machine will 
increase its upper threshold accordingly. Here also, a platelet volume histogram 
is obtained but there is no fitting of the curve (17). Optical platelet count (PLT-
O) is obtained in the RETIC chamber where the blood sample is mixed with a 
polymethine dye, which stains the reticulocyte and platelet RNA. Fluorescent 
platelet count (PLT-F) is obtained in a platelet specific PLT-F channel after the 
blood sample is stained with a platelet RNA specific fluorescent dye, oxazine. 
PLT-O and PLT-F are then obtained by the principle of flow cytometry as 
described in the previous section (27,28). PLT-F is considered to be superior to 
PLT-I in thrombocytopenic samples with closer concordance to the 
international reference method (29,30). 
 
3. Mindray® BC-6800 (Shenzhen, China): This analyser provides two different 
platelet counts, Impedance and optical fluorescence based. Impedance platelet 
count uses coulter principle and is similar to that described above. The 
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fluorescent platelet count (PLT-O) is obtained in the RETIC chamber after 
staining with an asymmetric cyanine fluorescent dye which stains platelet and 
reticulocyte RNA and count is obtained by principle of flow cytometry as 
described above (31). 
 
PLATELET MESSENGER RNA AND RETICULATED PLATELETS 
Since platelets are without a nucleus, they are incapable of synthesizing their own 
Messenger RNA (mRNA), which is required for protein synthesis. Research in recent 
years have shown that platelets have up to 3000 – 6000 copies of mRNA which is 
packaged into them by the megakaryocytes. Along with mRNA, platelets also receive 
ribosomes, microRNAs that regulate translation of mRNAs and initiation and 
termination factors required for mRNA translation from the megakaryocytes. It is now 
believed that platelets have distinct pools of mRNA; one pool which is constitutively 
expressed in resting platelets and a second pool whose expression is based on the 
signaling by integrins. Platelet mRNA is also more stable than previously thought as it 
is very rich in Poly (A) tails which retard RNA degradation (32)(33). 
Ingram and Coopersmith first described reticulated platelets in 1969 through an 
experiment they conducted on Beagles. They observed the presence of large platelets 
in the peripheral blood of these dogs following acute blood loss. These platelets had a 
high mean volume and when stained with a supra vital dye, New Methylene Blue, 
showed coarse punctate reticulum like structures (RNA) which were either concentrated 
in the center of the platelet or seen more dispersed throughout its cytoplasm. These were 
considered to be newly released platelets from the bone marrow which were being seen 
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in increased numbers following the hematological insult and they were called 
reticulated platelets or megathrombocytes. Studies in the 1970’s also showed that 
reticulated platelets were more functional and that their presence had a good co-relation 
with the number of megakaryocytes in the bone marrow in conditions like Immune 
Thrombocytopenic Purpura (ITP), Systemic Lupus Erythematosus (SLE), 
Disseminated Intravascular Coagulation (DIC), Hypersplenism and Aplastic anaemia 
(34). It was also shown that platelets decrease in size in circulation as they age, further 
adding strength to the point that reticulated platelets were indeed newly released 
platelets (35,36). Shulman et al. in 1968 showed that non-splenectomised individuals 
had a longer bleeding time that splenectomised individuals at the same platelet counts, 
thereby suggesting that reticulated platelets were sequestered in the spleen for up to 2 
days following their release from the bone marrow which probably explains the reason 
as to why they are seen only infrequently in the normal population (37). It has also been 
shown by in vivo biotinylation that reticulated platelets have a lifespan of around 24 
hours (38).  In light of these early investigations, reticulated platelets were thought to 
be more functional as well as a potential indicator of thrombopoiesis (8). An objective 
way of quantifying reticulated platelets came about in 1990 when Kienatz and Schmitz 
described the use of whole blood flow cytometry using a fluorescent dye called Thiazole 
orange, which bound to RNA. Analysis was done in EDTA anticoagulated blood and 
after gating the platelet population based on forward and side scatters, the percentage 
of Thiazole orange positive platelets are calculated. Reticulated platelets had more RNA 
and hence would bind to more Thiazole orange, thereby emitting fluorescence (39). 
This method had issues with standardization due to differences in incubation times, 
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thiazole orange concentrations and different gating strategies used, which kept changing 
from laboratory to laboratory. This led to the publication of very wide reference ranges 
(1 – 15%) and poor agreement between laboratories (40). Another main problem faced 
was the fluorescence labeling of nucleotides present in platelet dense granules leading 
to a non-specific fluorescence. In addition, this was also a highly operator dependent 
method and relatively expensive and thus its use was limited to research purposes 
(41,42). 
In spite of these limitations, reticulated platelets have been widely studied as a non-
invasive measure of platelet kinetics to differentiate between destructive and 
hypoplastic causes of thrombocytopenia. A study by Rinder et al. showed that an 
increased percentage of reticulated platelets in the setting of thrombocytopenia 
correlated well with increased megakaryocyte proliferation in the bone marrow whereas 
a decreased percentage of reticulated platelets indicated a decreased number of bone 
marrow megakaryocytes. The percentage of reticulated platelets were also found to be 
significantly higher in individuals with immune thrombocytopenia (38.6 ± 27.4%) 
when compared to patients on chemotherapy (7.2 ± 3.3%) and normal controls (2.9 ± 
2.2%). This study also reported that 17% of cases of ITP had reticulated platelet 
percentage values similar to that of the control population and this was attributed to a 
poor thrombopoietic response (29). Salvagno et al. in 2005 also reported similar 
findings with a significantly higher percentage of reticulated platelets seen in patients 
with ITP, SLE, DIC, TTP and liver cirrhosis with hypersplenism when compared to 
normal controls (laboratory reference range taken as 6.13 ± 3.09%).  The highest 
percentage of reticulated platelets was seen in patients with ITP (67.81 ± 18.79%) (44). 
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These findings were reflected in other studies as well leading to reticulated platelet 
percentage being considered as a cost effective and non-invasive test to replace a bone 
marrow examination which is the investigation of choice to diagnose a hypoplastic 
cause of thrombocytopenia (45,46). 
Following this, studies were directed at looking at platelet kinetics in patients on 
chemotherapy and post hematopoietic stem cell transplant (HSCT) to see whether 
reticulated platelets could be used as a marker for platelet recovery. Salvagno et al. also 
studied patients with hematological malignancies on chemotherapy and noted that the 
percentage of reticulated platelets was similar to the control population during the 
myeloablative phase (10.4 ± 9.02%) and that it increased to significantly higher levels 
in the recovery phase (35.45 ± 6.11%) (44). Wang et al. studied platelet kinetics in 
patients on chemotherapy and noted that the percentage of reticulated platelets 
increased significantly during the platelet count nadir, when platelet recovery was 
imminent. They suggested that a reticulated platelet percentage of 17% could predict 
platelet recovery within 48 hours with a negative predictive value of 91% and positive 
predictive value of 82% (47). Chaoui et al. observed that a reticulated platelet count of 
7% could predict platelet recovery in 4 days in patients post autologous stem cell 
transplant (48). Similarly, Michur et al. noted that the reticulated platelet percentage 
peak preceded platelet recovery by 3 days in patients post allogeneic stem cell transplant 
for various hematological malignancies (49). These studies showed that reticulated 
platelet percentage could be a useful tool to predict platelet recovery and thereby limit 
unwanted platelet transfusions in these conditions. 
In addition to these, an elevated percentage of reticulated platelets in the absence of 
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thrombocytopenia have been found to be a useful predictor of adverse outcome in 
diseases associated with increased platelet turnover like pre-eclampsia, graft versus host 
disease (GVHD), thromboembolism associated with thrombocytosis and acute 
myocardial infarction (50–53). Studies have also shown that the percentage of 
reticulated platelets is significantly higher in patients with sickle cell anaemia in vaso-
occlusive crisis, patients on hemodialysis or peritoneal dialysis and in critically ill 
patients with impending sepsis (54–56). These findings have helped improve the 
understanding of platelet kinetics in these disease processes. 
 
AUTOMATED METHODS FOR RETICULATED PLATELET ANALYSIS 
To overcome the issues faced by flow cytometric analysis of reticulated platelets, 
automated methods for the same were introduced in the 1990’s. The first fully 
automated method of reticulated platelet analysis was introduced by Toa Medical (later 
Sysmex® Corporation) in the R-3000, a dedicated reticulocyte analyser. Here, 
Auramine O was used as the RNA binding fluorescent dye and a 488nm argon laser 
was used as the light source. Forward scattered and side fluorescent light was collected 
to give information on cell size and RNA content respectively and in this way, 
reticulated platelets were differentiated and counted (57). In the later series of Sysmex® 
analysers; Sysmex® XE 2100 and the Sysmex® XE 5000, reticulated platelet analysis 
was incorporated into the complete blood count analysers and was given the new term 
Immature Platelet Fraction (IPF). These instruments used a 633 nm red diode laser as 
the light source and an asymmetric cyanine fluorescent dye belonging to the 
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polymethine family of dyes, which preferentially binds RNA. IPF was measured in the 
Reticulocyte (RETIC) channel. Forward scattered light (cell volume information) and 
side fluorescent light (RNA content assessment) are analysed and a specialized 
computer algorithm (XE Pro-Series, Sysmex®, Japan) applies specific gates to 
differentiate immature from mature platelets using intensities of forward scattered light 
and fluorescence. This software categorizes platelets with the highest 3% fluorescence 
as immature platelets (58). This is then represented on a scatter plot with blue dots 
representing mature platelets and green dots representing immature platelets. This 
channel also provides the optical platelet count (PLT O). IPF is provided as a percentage 
of the total optical platelet count. This method had a low coefficient of variation and an 
initial performance evaluation had suggested a good stability of the parameter for up to 
48 hours both at ambient laboratory temperatures and under refrigerated conditions 
(59). However, further studies highlighted a lack of stability with differences in reported 
stability times ranging from up to 4 hours to 24 hours with progressive increase in IPF 
when measured beyond these time intervals (60–62). This was attributed to the non-
specific staining of the polymethine dye to the cytoplasmic fragments of white blood 
cells (WBCs) which had disintegrated during storage (63). 
An improvement on this method was introduced in the Sysmex® XN series that is the 
latest technology available on the market. Here, the fluorescent dye was changed to an 
oxazine, which binds more specifically to platelet RNA in the rough endoplasmic 
reticulum and mitochondria. In addition, a dedicated chamber was added for 
measurement of IPF along with the fluorescent platelet count (PLT-F) (31). This 
improved the stability of the parameter for up to 48 hours both at room temperature and 
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at 4°Celsius (27). 
Mindray® BC-6800 (Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China) is 
another hematology analyser that also provides an IPF. Here, analysis is carried out in 
the reticulocyte chamber after addition of an asymmetric cyanine fluorescent dye which 
binds to platelet and reticulocyte RNA (64). Forward scattered laser light and side 
fluorescent laser light is collected to provide an optical platelet count (PLT-O) and the 
IPF. 
Abbott CELL-DYN Sapphire® hematology analyzer (Abbott Diagnostics, Santa Clara, 
California also measures reticulated platelets (retPLT) along with the assay for 
reticulocytes. Pre-diluted blood is mixed with a proprietary fluorescent dye called 
CD4K530 and is passed through a flow cell with a 488 nm green laser. Scattered light 
is collected at 3 different angles and fluorescent intensity is also measured. Then a 
specially developed algorithm is used to quantify the retPLT, which is expressed as a 
percentage of the total platelet count (65). 
As of now, there is no universally accepted reference range for IPF as it can vary 
between analysers due to differences in analytical principles and between populations 
due to ethnic variations. Hence, laboratory specific reference ranges are to be used (31). 
 
UTILITY OF IPF IN THE DIAGNOSIS OF THROMBOCYTOPENIA 
Briggs et al. published the first study looking at the clinical utility of IPF in 2004. The 
study was done on the Sysmex® XE series and stated that the most significant increase 
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in IPF was seen in individuals with ITP (mean 22.3%, range 9.2 - 33.1%) and TTP 
(mean 17.2%, range 11.2 - 30.9%). The normal range was taken as 1.1 – 6.1%. They 
also noted that the IPF% fell as the platelet count improved. The test was found to be 
reproducible with a CV of <10% (59). A study by Abe et al. also had similar findings 
with IPF being significantly higher in ITP and in the recovery phase post chemotherapy 
when compared to patients with aplastic anaemia, MDS, leukemias and lymphomas. 
They also stated that mean platelet volume was significantly higher in ITP than in the 
recovery phase of chemotherapy. They suggested an IPF cut off of 7.7% to distinguish 
ITP from hypo-productive causes of thrombocytopenia with a sensitivity of 88% and 
specificity of 85.7% (66). Adley et al. studied IPF in patients with acute and chronic 
ITP and compared it to patients on chemotherapy and found out that the IPF was 
significantly higher in patients with ITP and more so in patients with chronic ITP. They 
suggested an IPF cut off of 9.4%, which could pick out patients with ITP with a 
sensitivity of 86.8% and specificity of 92.6%. They observed a significant negative 
correlation between platelet count and IPF and also suggested that IPF could be a good 
prognostic marker for the development of chronic ITP (67). Kickler et al. also 
concluded that IPF was significantly higher in patients with platelet destruction (ITP 
and DIC) and that an IPF of > 9% was 100% specific for patients with peripheral platelet 
destruction. In this study also the IPF of patients with a regenerating marrow, though 
higher than the control population, was still significantly lower than in patients with 
platelet destruction (68). Strauss et al. conducted a study in the pediatric population to 
differentiate between ITP and Acute lymphoblastic leukemia (ALL) based on IPF and 
found that IPF was significantly higher in both the patient populations, but more so in 
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patients with ITP. This was interesting as ALL is considered to be a hypo-productive 
cause of thrombocytopenia (69). Pons et al. and Koike et al. also reported similar 
findings and in addition showed that there was a good correlation between reticulated 
platelet measurement by conventional flow cytometry and IPF% (70,71). Miyazake et 
al studied the utility of IPF in the diagnosis of macrothrombocytopenias and reported 
that in MYH9 related disorders; the IPF was five times that seen in ITP (48 ± 1.9%) and 
twice as that seen in other macrothrombocytopenias like Bernard Soulier syndrome, αδ 
storage pool disease (72). All these studies had been performed on Sysmex® XE 
instruments.  
UTILIY OF IPF IN THE PREDICTION OF PLATELET RECOVERY 
Hematopoietic stem cell transplant (HSCT) is a major treatment option for many 
hematological diseases like leukemias, lymphomas, bone marrow failure syndromes, 
hemoglobinopathies etc. This can be either allogeneic (stem cells from one individual 
are introduced into another) or autologous (previously harvested stem cells are re-
introduced into the same individual). Prior to transplant, the recipient’s hemato-
lymphoid system is almost completely suppressed by a preparative regimen, which can 
be myeloablative or non-myeloablative. This is to either completely eradicate malignant 
cells from the system or to prevent the recipient’s immune cells from attacking the graft. 
So following the transplant, the recipient is usually in a phase of profound 
immunosuppression from which they have to recover as and when the introduced stem 
cells engraft and start producing progeny. Two main blood cell lines that are monitored 
for this are the neutrophils and platelets. According to the European Society for Blood 
and Marrow Transplantation, neutrophil engraftment after transplantation is defined as 
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an absolute neutrophil count (ANC) exceeding 500/µL for 3 consecutive days. The first 
of these 3 days is taken as the day of engraftment and usually occurs within 2 weeks in 
granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood grafts. 
Platelet recovery is defined as the time after transplantation needed to achieve a blood 
platelet count exceeding 20,000/µL without transfusion support for 7 consecutive days 
(73,74). It is important to know the time of neutrophil and platelet engraftment, as 
delayed engraftment can be a sign of infection, GVHD or engraftment failure. Ongoing 
studies have shown that neutrophil engraftment can be predicted reliably by the 
immature reticulocyte fraction which is provided by some hematology analysers (75). 
In the same way, studies are now showing that IPF can predict platelet recovery as well 
in these patients since it has proved to be a reliable marker of thrombopoietic activity. 
Chemotherapy for various malignancies is also a condition where there is marked 
suppression of the hematopoietic system leading to severe thrombocytopenia. In these 
cases as well as in patients post HSCT; the transfusion trigger for platelets is 
<10,000/µL (76). Hence, an early marker for platelet recovery would be useful to 
prevent un-necessary prophylactic platelet transfusions in these patients. 
Morkis et al. serially studied IPF measurements in 24 patients post autologous and 20 
patients post allogeneic HSCT and suggested that an IPF cut off of >6.2% could predict 
platelet engraftment in up to 90% of patients and that the peak IPF% was seen before 
an increase in platelet count (77). Goncalo et al. conducted similar studies in 46 patients 
post allogeneic HSCT and stated that IPF could predict platelet engraftment up to 2 
days before increase in platelet count (78). Takami et al. concluded that the IPF rose 
transiently >3% after around 11 days post transplant and that this rise occurred 1 day 
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prior to platelet engraftment (79). Van der Linden et al. on studies conducted on the 
Sysmex® XN analyser proposed an IPF cut off of 5.3% for platelet recovery within 2 
days in patients post autologous HSCT. They found that the effect of platelet transfusion 
on IPF was unequivocal (80). This was unlike some other studies by Bat et al. and 
Briggs et al., which had shown that IPF was reduced transiently by platelet transfusions. 
This was thought to be due to the suppression of thrombopoietin response or due to 
dilution of circulating immature platelets. They also had a similar finding of IPF being 
elevated 1 – 2 days prior to platelet count increase in post HSCT patients. Bat et al. also 
suggested that the Absolute Immature Platelet Number (AIPN) which is obtained by 
multiplying the IPF by the circulating platelet count / 100 is a better indicator of platelet 
recovery since it was not affected by platelet transfusion (81,82). Yamaoka et al. 
published that platelet recovery occurred earlier in patients undergoing HSCT with peak 
IPF% >10% than in those with IPF% peak values ≤ 10% and that in these patients, 
platelet recovery occurred within 2 – 6 days of peak IPF. Comparable findings were 
also seen in patients on chemotherapy for hematological malignancies (83). Another 
study showed similar results in the pediatric population undergoing HSCT or 
chemotherapy for various malignancies (84). In contrast, Have et al. studied serial IPF 
values in children on chemotherapy and said that there was no difference in platelet 
recovery between patients with an IPF% peak value >10% or an IPF% peak value ≤ 
10%. They instead concluded that a significant increase in the AIPN of up to 0.6 x 109/L 
was seen 24 – 48 hours prior to platelet count recovery and that AIPN was not affected 
by platelet transfusions (85). 
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OTHER PLATELET PARAMETERS AND THEIR UTILITY 
In addition to different types of platelet counts and IPF, hematology analysers also 
provide other parameters, mainly related to platelet volume. Most of these parameters 
show variations between hematology analysers due to differences in how platelets are 
counted (impedance / optical based) (86). As a result, it is necessary for laboratories to 
use their own analyser as well as population specific reference ranges. These other 
platelet parameters or platelet volume indices are listed out as follows with their means 
of derivation and utility in the diagnosis of platelet disorders: 
 
1. Mean Platelet Volume (MPV):  In impedance counters, it is derived from the platelet 
size distribution curve. In optical scatter based counters, it is calculated from the modal 
platelet size or from Plateletcrit (PCT%) using the formula - 
MPV (fL) = PCT (%) / Platelet count (103/µL) (86,87). In general, a reference range of 
7 – 12fL is used, but laboratory specific reference ranges are preferred (88). MPV 
increases progressively with storage in EDTA anticoagulated blood samples due to 
platelet swelling (89). MPV is inversely correlated with platelet count (90,91). Since 
newly released platelets are larger in size, studies were conducted to see if MPV could 
be an indicator of thrombopoiesis. Studies have shown that an elevated MPV can 
distinguish between hypoplastic and destructive causes of thrombocytopenia (92,93).  
Noris et al stated that an MPV > 12.4fL (Sysmex® XE) could distinguish between 
inherited macrothrombocytopenias and ITP with sensitivity of 83% and specificity of 
89% (94). When this cut off was used in a study with larger patient numbers, a similar 
specificity was obtained (95). 
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2. Plateletcrit (PCT): It is defined as the volume of circulating platelets in a unit volume 
of blood and is expressed as a percentage (6). It is provided by certain analysers and 
can be either directly measured as equivalent to the sum of platelet impulses which are 
individually detected by means of the impedance measurement principle (Sysmex® 
analysers) or can be derived as the product of MPV and Platelet count (Mindray® 
analysers) (88). It has been suggested that PCT could be a better predictor of competent 
hemostasis than platelet count since it incorporates both platelet count and platelet 
volume (86). One study has shown that PCT is significantly lower in patients with ITP 
when compared to patients with thrombocytopenia secondary to bone marrow failure 
(67). 
 
3. Platelet Distribution Width (PDW): It is calculated from the platelet histogram as the 
width of the size distribution curve at the 20% level of the peak and is expressed in 
femtoliters (87). A few studies have shown that PDW was significantly increased in 
ITP when compared with hypoproductive causes of thrombocytopenia implying that it 
could be used as a useful adjunct in these differential diagnosis (92,96). PDW is also 
significantly increased in essential thrombocytosis and can be used to distinguish it from 
reactive thrombocytosis (86). 
 
4. Platelet Large Cell Ratio (P-LCR): It is defined as the number of cells falling above 
the 12 fL threshold divided by the total number of platelets and is expressed as a 
percentage. A few studies have shown that P-LCR is directly proportional to IPF and 
that P-LCR is significantly elevated in ITP when compared to hypo-productive causes 
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of thrombocytopenia, thereby serving as an additional parameter to distinguish between 
the two etiologies (67,96,97).  
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AIMS 
 
1. To characterize the immature platelet fraction (IPF) derived from the 
automated hematology analyzers Sysmex® XN9000 and Mindray® BC6800 in 
specific cohorts of thrombocytopenic patients and its comparison to normal 
controls at a tertiary care center in India. 
 
2. To serially monitor IPF in patients undergoing hematopoietic stem cell   
transplantation and correlate the trends in IPF to the timing of platelet recovery.  
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OBJECTIVES 
 
1. To determine the IPF and other platelet indices like Mean platelet volume, 
Plateletcrit, Platelet distribution width and Platelet large cell ratio in specific 
cohorts of patients with thrombocytopenia using the Sysmex® XN9000 and 
Mindray® BC 6800 automated hematology analyzers.  
 
2. To determine whether these platelet indices can be used to reliably distinguish 
between different causes of thrombocytopenia.  
 
3. To correlate these indices with morphological features of platelets on a stained 
peripheral smear.  
 
4. To analyze the trends in IPF in patients undergoing hematopoietic stem cell 
transplantation and to see whether it can be a reliable predictor of platelet 
recovery. 
 
5. To get the normal reference range for IPF% in adults and children in the 
laboratory.  
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MATERIALS AND METHODS 
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This study was conducted in the Department of Transfusion Medicine and 
Immunohematology in conjunction with the Department of Clinical Hematology, 
Christian Medical College, Vellore. 
The study was approved by our Institutional Review Board. 
The study duration lasted from April 2015 to December 2015.  
In the initial study protocol submitted (annexure 2) we had also included two 
additional disease groups for IPF trend analysis in a recovering marrow i.e. patients 
with Aplastic anaemia on Anti Thymocyte Globulin therapy and patients with Acute 
myeloid leukemia on chemotherapy. However, during the duration of study, the 
number of patients that fulfilled these criteria were very small (N=7 and N=9 
respectively) and hence the data that we have from these patient groups were not 
analysed.  
 
I. Characterization of platelet indices in patients with thrombocytopenia and 
their correlation with platelet morphology on peripheral smear.  
Patients with thrombocytopenia usually present to the Hematology outpatient 
department (OPD) with bleeding symptoms or are incidentally picked up as part of a 
routine evaluation. In our hospital, every patient presenting for the first time to the 
Hematology OPD are subject to a complete blood count evaluation if deemed 
necessary by the clinician. These samples are collected by an evacuated tube system 
and analysed within 4 hours of collection in any one of the three automated 
hematology analysers (i.e. UniCel® DxH 800, Sysmex XN® 9000 and Mindray BC® 
6800) in place in our laboratory. Peripheral smears are automatically made for  
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samples with platelet counts less than 100000/µL using the using UniCel® DxH 
Slidemaker Stainer according to our laboratories’ smear review criteria. A platelet 
count of less than 100000/µL is considered to be significant and the next step usually 
entails a bone marrow examination (trephine biopsy and aspirate smears) to assess the 
adequacy of megakaryocytes and the presence/absence of primary bone marrow 
pathology.  Additional investigations if needed are carried out and a final diagnosis is 
then given with treatment being initiated accordingly. 
 
Inclusion criteria:  
• All patients presenting for the first time to the Clinical Hematology OPD in our 
hospital with an initial platelet count of less than 100000/µL were enrolled in 
the study irrespective of whether or not they had had previous treatment for 
their condition from another hospital. This stand was taken since our institution 
is a tertiary referral care center.  
 
Exclusion criteria:  
• Patients who had presented to the Hematology OPD for similar or other 
hematological complaints prior to the start of the study period. 
• Cases in which peripheral smear slides were not available for review. 
 
Patient demographics, diagnoses, bone marrow trephine and aspirate reports were 
retrieved from the clinical workstation database. Peripheral smear slides were 
retrieved from the slide archival files. All patient diagnoses and classifications were  
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made based on established international guidelines. The presence or absence and 
adequacy of bone marrow megakaryocytes were recorded from bone marrow trephine 
or aspirate reports in which megakaryocytes had been graded as adequate, increased, 
decreased, absent and with or without dysplastic changes based on accepted 
guidelines.   
 
The patients who were finally included in the study encompassed all the patient 
groups mentioned in our approved study protocol. Patients diagnosed with chronic 
liver disease from Gastroenterology OPD (as mentioned in our protocol) were not 
included in the study as we encountered a good number of patients with 
thrombocytopenia due to chronic liver disease or hypersplenism presenting to the 
Hematology OPD as well. 
 
Sample collection and analysis: 
Blood samples were collected as part of routine clinical workup into Vacutainer tubes 
(Vacuette®, Greiner Bio-One, Kremsmünster, Austria), anticoagulated with K2EDTA 
(Ethylenediamenetetraacetic acid dipottasium salt). The blood left over in the tubes 
after initial routine complete blood count was used for this study purpose. For this 
second run, the samples were analysed within 24 hours of collection with blood 
samples being stored at 22-24° Celsius (ambient laboratory temperature). Samples 
were analysed in two hematology analysers, Sysmex XN® 9000 (in the DIFF + PLT-F 
mode) and Mindray BC® 6800 (in the CDNR mode).  
	 35	
The impedance platelet counts (PLT-I), fluorescent platelet counts (PLT-F, in 
Sysmex), optical platelet counts (PLT-O, in Mindray) and other platelet parameters  
like MPV, PCT, PDW and P-LCR were retrieved from the system database and 
tabulated in an MS Excel sheet. In those situations where an MPV was not provided 
by either of these two analysers, patient results from the initial sample run were 
retrieved. If the initial run was carried out on the UniCel® DxH 800 Coulter 
hematology analyser, an MPV would invariably have been provided and this value 
was taken for analysis. 
 
Peripheral smear examination: 
Modified Wright-Giemsa stained peripheral blood smears were made for all the study 
samples within 4 hours of sample collection using UniCel® DxH Slidemaker Stainer 
(Annexure 4). These were evaluated for the following: 1. Platelet estimate on peripheral smear (Annexure 5) - One platelet per oil 
immersion field in an area where the red blood cells are just overlapping was 
equated to 15000 platelets/µL of blood. 20 such fields were counted and the 
average platelet count was calculated. 2. Platelet size – A maximum of 100 and a minimum of 5 platelets (based on the 
baseline platelet count) were analysed on each peripheral smear and they were 
sized into the following groups: 
(a) Normal – Normal sized platelets (1.5 - 3µm in diameter) . 
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(b) Large – Platelet size slightly smaller than that of a red blood cell (> 4µm in 
diameter) (7) or slightly smaller than the nucleus of a small lymphocyte, 
keeping the nucleus of a small lymphocyte as an index.  
(c) Giant – Platelet size larger than that of a red blood cell.  
      3. Platelet cytoplasm – The cytoplasm of all the sized platelets were categorized 
 according to their colour as follows: 
 (a) Grey 
 (b) Bluish grey  
 (c) Blue 
 
II. Trends of IPF in patients undergoing hematopoietic stem cell transplantation and its 
relationship to platelet recovery and platelet transfusion requirements. 
 
Inclusion criteria: 
• Patients diagnosed with Aplastic Anaemia or Thalassemia and undergoing 
allogeneic hematopoietic stem cell transplantation. 
• Patients diagnosed with a Lymphoma or Multiple Myeloma and undergoing 
autologous hematopoietic stem cell transplantation. 
 
Patient demographics, diagnoses, conditioning regimens used, total number of platelet 
transfusions and complications during transplant were retrieved from the clinical 
workstation and transplant summaries. 
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Sample collection and analysis: 
As part of routine protocol, blood samples are collected from these patients at the 
bedside through an evacuated tube system every day or every alternate day and sent to 
our laboratory for complete blood counts. The sample left over after the initial 
analysis was then run again within 24 hours of storage at ambient laboratory 
temperature on Sysmex XN®9000 (in the PLT-F mode) and Mindray BC®6800 (in the 
CDNR mode). PLT-F/PLT-O counts and IPF values were retrieved from the system 
database and tabulated in an MS Excel sheet. Serial samples from each patient were 
analysed in this way until platelet recovery (defined as the third day of an unsupported 
platelet count of more than 20000/µL).  
We have collected serial samples rather than timed samples as mentioned in our 
protocol (annexure 2) since we did not want to interfere with routine practices for 
peripheral blood count monitoring post HSCT that are in place in our institution. 
 
III. Reference range calculation for platelet indices 
Since we did not have laboratory and analyser specific reference ranges for MPV, IPF, 
PCT, P-LCR and PDW, it was decided to calculate the reference ranges for the same 
in adults and children (<18 years).   
For reference range calculation in adults, blood samples from 248 voluntary blood 
donors presenting to our blood bank were run within 4 hours of collection in Sysmex 
and Mindray analysers. For reference range calculation in children, blood samples 
from 27 healthy children being worked up as prospective stem cell donors and 
presenting to our HLA testing laboratory were run within 4 hours of collection in the 
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Sysmex analyser. All the samples had a normal platelet distribution histogram with no 
system / suspect flags. 
The Kolmogorov-Smirnov test for normality was performed on all the platelet 
parameters and they were all found to have a p value <0.05 which is indicative of a  
non- normal distribution. Hence, reference ranges for MPV, IPF, PDW, P-LCR, PCT 
and PDW were calculated using 5th and 95th percentiles as cut offs.  
 
IV. Assessment of stability of platelet counts and platelet indices 
Since literature has given contradicting information on stability of platelet parameters 
on the same as well as different analysers, we decided to carry out stability tests of 
these parameters on the XN as well as the Mindray platforms before the start of the 
study. This was carried out as follows: 
Paired blood samples were collected from 23 healthy, voluntary blood donors into 4ml 
vacutainer tubes with dipottasium ethylenediamenetetraacetic acid as an 
anticoagulant. One set was stored at 22-24°C (ambient lab temperature) & other at 2-
8°C (specimen storage refrigerator).  Platelet parameters were measured every 4th hour 
till 24 hours, then at 32nd and 48th hours on both analysers. Results were tabulated in 
an Excel sheet and analysed using SAS 9.4 software.  
This data was also used to study the agreement between the two analysers using 
Bland-Altman agreement plots. 
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ANALYTICAL PRINCIPLES 
 
Sysmex® XN 9000 
PLT-I is measured in the RBC/PLT channel using the principle of electrical 
impedance after treating the aspirated blood with a diluent, and the platelets are 
counted and sized based on the number and peak of voltage pulses obtained. The final 
platelet count is given from an algorithm that derives the data from the area under the 
curve of the platelet histogram. PLT-O is measured in the RETIC channel after 
staining with a nucleic acid binding dye called Polymethine which is an asymmetric 
cyanine fluorescent dye. PLT-F and IPF are measured in the PLT-F channel after 
treating the blood with a diluent (Cell pack DCL®) and staining with a proprietary 
dye, which belongs to the class of Oxazine dyes. This dye is said to be more specific 
in binding to the nucleic acids within the mitochondria and ribosomes of platelets. The 
platelet count here is obtained from the scatter plot of Forward Scatter against Side 
Fluorescence. From the fluorescent platelet count, the immature platelet fraction is 
derived using a gating mechanism, which analyses platelets above a certain 
fluorescent threshold and gives the IPF as a percentage of the total fluorescent platelet 
count.  
The MPV, PCT, PDW and P-LCR are obtained from the platelet histogram, which is 
obtained from the RBC/PLT chamber.  
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Mindray® BC 6800 
PLT-I, MPV, PCT, PDW and P-LCR follow similar measurement principles as 
detailed above. PLT-O is measured in the RETIC chamber after staining with an 
asymmetric cyanine fluorescent dye and the IPF is derived as a percentage of the total 
optical platelet count. 
 
 
STATISTICAL ANALYSIS 
Statistical significances between different subgroups of patients with 
thrombocytopenia were calculated using independent two-sample t-tests or Mann-
Whitney U-tests depending on the normality of distribution. 
P-value of less than 0.05 was considered to be statistically significant. 
Software STATA version 11.0 was used for statistical analysis. 
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ILLUSTRATIONS
	                          
       Figure 1: Normal PLT-F scatter plot on Sysmex XN     
9000 in an individual with normal IPF. 
         Legend: PLT-F - Fluorescent platelet; FSC - Forward 
scatter; SFL - Side fluorescence. 
 
 
                                                   
  Figure 2: Normal platelet histogram on Sysmex XN 9000. 
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                         Figure 3. Normal PLT-O scatter plot on Mindray BC 6800 
  in an individual with normal IPF. 
Legend: PLT-O - Optical platelet; FS - Forward scatter;  
SFL - Side fluorescence. 
 
 
 
 
 
 
 
 
         Figure 4. Normal platelet histogram on Mindray BC 6800. 
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                             Figure 5. PLT-F scatter plot of a patient with high 
IPF (IPF = 71%). 
 
 
 
 
 
 
                                      
   Figure 6. Platelet histogram of the same patient  
as above reflecting the presence of giant platelets. 
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   Figure 7. Normal sized platelets in a representative field used 
 for platelet counting on peripheral smear (Modified  
  Wright-Giemsa stain, Oil immersion - 1000X magnification). 
 
 
 
      Figure 8. A large platelet [indicated by black arrow head];  
equal to the size of a normocytic red blood cell and  
with deep blue cytoplasm - Immature platelet.  
  (Modified Wright-Giemsa stain, Oil immersion - 1000X magnification). 
Red blood cells 
just overlapping 
each other 
	 
          Figure 9. A giant platelet (larger than the size of a normocytic 
 red blood cell) with deep blue cytoplasm (Modified  
   Wright-Giemsa stain, Oil immersion - 1000X magnification). 
 
 
 
                                         Figure 10. A giant platelet with blue cytoplasm [indicated by black           
                 arrow head] in a patient with ethnic macrothrombocytopenia and         
                 other normal platelets with grey-blue cytoplasm.  (Modified Wright-
Giemsa stain, Oil immersion - 1000X magnification).
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RESULTS 
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I. REFERENCE INTERVALS FOR PLATELET PARAMETERS 
Several quantitative platelet parameters are now available on hematology analyzers. 
The following are directly measured; Platelet count (Impedance, Optical/ 
Fluorescence) and Immature platelet fraction and the remaining i.e. Mean platelet 
volume, Platelet distribution width, Plateletcrit and Platelet large cell ratio are derived 
from other primary modalities. We have determined reference intervals for these using 
the normal population that we studied for adults and children. Since all parameters 
had a non-parametric distribution, reference intervals were calculated using the 5th and 
95th percentiles (Table 1).  
 
Table 1. The normal reference intervals obtained for our population on Sysmex 
XN9000 and Mindray BC6800. 
PARAMETER SYSMEX MINDRAY 
Median (5th – 95th percentile) Median (5th - 95th percentile) 
MPV (fL) 10.6 (9.5 - 12.1) 9.5 (8.3-11.2) 
IPF (%) 2.5 (1.1 - 6.1) 4 (1.6-8.9) 
PDW (fL)  12.6 (10.4-16.3) 15.9 (15.4-16.5) 
PCT (%) 0.3 (0.22-0.42) 0.28 (0.20-0.39) 
P-LCR (%) 30.1 (20.7-42.5) 23 (14.9-35.4) 
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Since there is a high prevalence of constitutional macrothrombocytopenia in 
individuals from North Eastern India who come to our institution, we calculated a 
separate set of reference intervals for them using data from 131 blood donors coming 
from these areas (Table 2). 
 
Table 2. Reference intervals obtained for North East Indian population on Sysmex XN 
9000. 
Parameter Reference intervals    (5th- 95th percentile) 
MPV (fL) 10.3 – 14.9 
IPF (%) 2.1 - 34.8 
PDW (fL) 12.0 - 24.1 
PCT (%) 0.19 - 0.37  
P-LCR (%) 27.8 - 64.2 
 
Table 3. Reference intervals obtained for children on Sysmex XN9000. 
Parameter Reference intervals    (5th- 95th percentile) 
MPV (fL) 8.6 – 11.3 
IPF (%) 0.4 – 3.1 
PDW (fL) 7.9 – 14.8 
PCT (%) 0.22 – 0.47  
P-LCR (%) 13.4 - 36 
The difference between adult and child populations was probably due to the smaller 
sample size used in the reference interval calculation for children (N=27) when 
compared to the sample size of 248 in the reference interval calculation of the adult 
population. 
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II. AGREEMENT BETWEEN THE TWO ANALYSERS 
As a part of the standardization process, we performed Altman-Bland agreement 
statistics on the IPF data obtained from analysis on the Sysmex and Mindray 
platforms.  
 
 
Figure 1. Altman-Bland agreement plot for IPF (Immature platelet fraction) between 
the Sysmex and Mindray analysers. 
 
The above figure shows that majority of the data points fall within the 95% 
confidence intervals. There was no systematic bias observed between the two 
analysers. The Intra-class correlation coefficient was found to be 0.92 (95% CI: 0.81-
0.97) which suggested that there was a good agreement between the two analysers.  
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III. STABILITY OF PLATELET PARAMETERS ON THE TWO 
ANALYSERS 
Given the fact that clinical laboratories have different workflows based on where 
samples are sourced from and the need for add-on testing on samples already in the 
laboratory, stability of the measured parameter is an important consideration. We 
evaluated the stability of platelet parameters by timed repetitive analysis of samples 
stored at different temperature conditions up to 24 hours.  
 
Table 4. Time (in hours) within which samples have to be analysed on Sysmex and 
Mindray analysers to get reliable results when stored at two different temperatures. 
 
PARAMETER 
SYSMEX (IN HOURS) MINDRAY (IN HOURS) 
22-24oC 2-8oC 22-24oC 2-8oC 
IPF (%) 48 48 8 4 
MPV (fL) 24 4 24 4 
PLT F (x 109/L) 32 48 Not provided Not provided 
PLT I (x 109/L) 48 48 48 48 
PLT O (x 109/L) 48 48 48 48 
P-LCR (%) 32 0 32 0 
PCT (%) 48 24 48 24 
PDW (fL) 24 4 48 48 
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Figure 2. Serial IPF measurements over time in Sysmex (SX) and Mindray (MR) 
analysers in samples stored at 22-24°C (LAB) and 2-8°C (FRIDGE) temperatures. 
 
The IPF in the Sysmex analyser was stable up to 48 hours at both the storage 
conditions (Table 4) whereas the IPF obtained in the Mindray analyser was stable only 
up to 8 hours when stored at 22-24°C and up to 4 hours when stored at 2-8°C 
(indicated by red arrows in figure 2), beyond which, there was a significant rise in 
IPF% above the true value. 
 
Figure 3. Serial MPV measurements over time in Sysmex (SX) and Mindray (MR) 
analysers in samples stored at 22-24°C (LAB) and 2-8°C (FRIDGE) temperatures. 
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The MPV in both analyzers was unstable, with 24 hours of storage at 22-24°C being 
the latest by which a sample could be analysed to get accurate results on the Sysmex 
analyser (indicated by red arrows in figure 3). Beyond the stable time periods, there 
was a steady rise in MPV with time.	
Due to the lack of stability of IPF and MPV on Mindray, only Sysmex XN9000 was 
used for further study purpose. 
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IV. CHARACTERISATION OF IPF IN PATIENTS WITH 
THROMBOCYTOPENIA 
During the study period, we were able to recruit 200 patients who fulfilled our 
inclusion criteria. From this, we excluded 4 patients who did not have a final 
diagnosis because they were lost to follow up.  Our working sample size comprised 
196 patients. 
 
(A) PATIENT DEMOGRAPHICS  
Geographical regions: There was an even distribution of patients coming from all 
regions of the country. However, the local population accounted for 25% of the total 
patient number. Almost half (45%) of the patient population in our study were from 
Bangladesh and eastern states of India like West Bengal, Jharkhand, Bihar, Orissa, 
Tripura, Meghalaya and Assam.  
Figure 4. The geographical distribution of patients with thrombocytopenia. 
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Age: The majority of patients with thrombocytopenia (71%) were adults. The age at 
presentation ranged from 4 months to 76 years with a mean age of 32 years (Figure 5). 
All patients who were under the age of 18 were considered as children.	
 
. 
              Figure 5. The age wise distribution of patients with thrombocytopenia. 
 
Gender distribution: There was an almost equal distribution of thrombocytopenia 
among males and females (Figure 6).  
 
             Figure 6. The gender distribution of patients with thrombocytopenia. 
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(B) ETIOLOGIES OF THROMBOCYTOPENIA:	
 
The most common cause of thrombocytopenia in our study population fell under the 
broad category of platelet production defects (87 patients; 44%). 67 patients (34%) 
had thrombocytopenia due to increased peripheral destruction of platelets and 42 
patients had other causes of thrombocytopenia which did not fall under any of the 2 
main categories (Figure 7). 
 
Figure 7. The distribution of etiologies of thrombocytopenia. 
 
The individual patient diagnoses under each broad category of thrombocytopenia were 
as follows: 
     Table 5. Causes of peripheral platelet destruction. 
ETIOLOGY NUMBER 
Acute and Persistent Immune thrombocytopenic purpura (ITP) 30 
Chronic ITP 17 
Hypersplenism 20 
Total 67 
44%
34%
22%
ETIOLOGIES OF THROMBOCYTOPENIA
DECREASED PLATELET 
PRODUCTION
INCREASED PERIPHERAL 
DESTRUCTION
OTHER CAUSES
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The majority of patients (70%) with thrombocytopenia due to a peripheral destruction 
of platelets had ITP. The remaining patients had hypersplenism due to chronic liver 
disease or thalassemia (Table 5). 
 
     Table 6. Causes of decreased platelet production. 
ETIOLOGY NUMBER 
Aplastic anaemia 47 
Leukaemia 21 
Lymphoma/Myeloma 7 
Myelodysplastic syndromes (MDS) & Myeloproliferative 
neoplasms (MPN) 12 
Total  87 
 
Majority of patients (54%) with a hypoproductive cause of thrombocytopenia were 
diagnosed to have aplastic anaemia followed by 32% of patients having a marrow 
infiltrative pathology like leukemia, lymphoma or myeloma (Table 6). 
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Table 7. Other causes of thrombocytopenia. 
ETIOLOGY NUMBER 
Constitutional ethnic macrothrombocytopenia 12 
Megaloblastic anaemia 6 
Paroxysmal nocturnal haemoglobinuria 4 
Infections 3 
Chronic kidney disease 3 
Bernard Soulier syndrome 2 
Wiskott Aldrich syndrome 1 
Kasabach Merritt syndrome 1 
Drug induced 1 
Osteopetrosis 1 
MDS or MPN with adequate megakaryocytes 8 
Total  42 
 
Out of the patients with thrombocytopenia due to causes that did not clearly fit into 
either of the two broad categories described above, 28% had constitutional ethnic 
macrothrombocytopenia and 14% had megaloblastic anaemia (Table 7). 
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(C) PLATELET PARAMETERS IN PATIENTS WITH 
THROMBOCYTOPENIA: 
The median impedance platelet count in all patients with thrombocytopenia was 
23500/µl, ranging from a minimum of 1000/µl to a maximum of 97000/µl. 
Table 8. Platelet parameters in patients with thrombocytopenia due to decreased 
production of platelets or increased destruction of platelets and the statistical 
significance between the two groups. 
 
PARAMETER DECREASED 
PRODUCTION 
[MEDIAN (IQR)] 
PERIPHERAL 
DESTRUCTION 
[MEDIAN (IQR)] 
P-VALUE 
PLT I (/µl) 16000  
(9000 - 36000) 
 
30000 
 (12000 - 56000) 
<0.05 
PLT F (/µl) 15000  
(7000 - 29000) 
 
34000  
(12000 - 57000) 
<0.05 
Smear platelet 
count (/µl) 
 
11250 
 (4500 - 24750) 
24750  
(12000 - 46500) 
<0.05 
IPF (%) 6.6  
(4.6 - 10.1) 
 
15.5  
(9.9 - 27.8) 
<0.05 
IPF (%)  
(Excluding 
North East 
India) 
 
5.5  
(4.0 - 8.2) 
15.2  
(9.8 - 23.5) 
<0.05 
PCT (%) 0.03 
 (0.02 - 0.06) 
 
0.07  
(0.05 - 0.09) 
<0.05 
PARAMETER  [MEAN ± 2SD]  [MEAN ± 2SD] P-VALUE 
MPV (fL) 
 
10.4 
 (4.8 - 16) 
 
9.7 
(5.9 - 13.5) 
0.38 
PDW (fL)  13.4  
(9.6 - 17.2) 
 
16.1  
(10.1- 22.1) 
<0.05 
P-LCR (%)  36 
(17.8 - 54.2) 
44.6 
(26 - 63.2) 
<0.05 
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Since patients from the North Eastern parts of India, Bangladesh and Nepal have a 
high incidence of ethnic macrothrombocytopenia, we created another subset by 
excluding all patients from West Bengal, Jharkhand, Orissa, Bihar, Tripura, 
Meghalaya, Assam, Bangladesh and Nepal and looked at the IPF values in these 
individuals (N=48). The median IPF dropped from 6.6% (all cases of hypo-
production) to 5.5% when the North Eastern patients were excluded. 
Platelet count, IPF, PCT, PDW and P-LCR were all significantly lower in patients 
with thrombocytopenia due to decreased production than in patients with a peripheral 
destruction of platelets. MPV did not show a significant difference between the two 
groups (Table 8).  
 
Table 9. Platelet parameters in patients with ethnic macrothrombocytopenia and in 
patients with increased destruction of platelets 
 
PARAMETER MACROTHROMBOC 
YTOPENIA 
[MEDIAN (IQR)] 
PERIPHERAL 
DESTRUCTION 
[MEDIAN (IQR)] 
P-VALUE 
PLT I (/µl) 47500  
(45000 - 56000) 
30000 
 (12000 - 56000) 
<0.05 
PLT F (/µl) 67500  
(59500 - 78000) 
34000  
(12000 - 57000) 
<0.05 
Smear platelet 
count (/µl) 
 
66000  
(59250 - 79500) 
24750  
(12000 - 46500) 
<0.05 
IPF (%) 47.6  
(38.9 - 49.8) 
15.5  
(9.9 - 27.8) 
<0.05 
PARAMETER  [MEAN ± 2SD]  [MEAN ± 2SD] P-VALUE 
MPV (fL) 
 
10.5 
 (5.6 – 15.5) 
 
9.7 
(5.9 - 13.5) 
0.38 
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 Table 10. Platelet parameters in patients with ethnic macrothrombocytopenia and in    
patients with decreased production of platelets 
 
Patients with ethnic macrothrombocytopenia had significantly higher IPF and platelet 
counts than patients with either of the other two broad categories of thrombocytopenia 
(Table 10). PCT, PDW and P-LCR were not analysed as they were not provided by 
the analyser in patients with giant platelets due to lack of generation of a histogram. 
PARAMETER MACROTHROMBOC 
YTOPENIA 
[MEDIAN (IQR)] 
DECREASED 
PRODUCTION 
[MEDIAN (IQR)] 
P-VALUE 
PLT I (/µl) 47500  
(45000 - 56000) 
16000  
(9000 - 36000) 
 
<0.05 
PLT F (/µl) 67500  
(59500 - 78000) 
15000  
(7000 - 29000) 
 
<0.05 
Smear platelet 
count (/µl) 
 
66000  
(59250 - 79500) 
11250 
 (4500 - 24750) 
<0.05 
IPF (%) 47.6  
(38.9 - 49.8) 
6.6  
(4.6 - 10.1) 
<0.05 
PARAMETER  [MEAN ± 2SD]  [MEAN ± 2SD] P-VALUE 
MPV (fL) 
 
10.5 
 (5.6 – 15.5) 
 
10.4 
 (4.8 - 16) 
1 
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The bone marrow trephine biopsy reports where available were reviewed for all 
patients. They were classified into two groups: where there appeared to be adequate 
megakaryocytes in the marrow and those with decreased megakaryocytes and the IPF 
was compared between the two groups.  
 
Table 11. IPF in patients with adequate bone marrow megakaryocytes and decreased 
bone marrow megakaryocytes. 
 
ADEQUATE 
MEGAKARYOCYTES 
DECREASED 
MEGAKARYOCYTES 
P-VALUE 
Number of 
patients 54 33  
IPF (Median 
[IQR]) 14.1 (8.1-25.3) 8.3 (5.4-12.8) <0.05 
 
Median IPF in patients with adequate bone marrow megakaryocytes was 14.1% which 
was significantly higher than in patients with decreased bone marrow megakaryocytes 
who had a median IPF of 8.3% (Table 11). 
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(D) UTILITY OF IPF TO DISTINGUISH BETWEEN PATIENTS WITH 
THROMBOCYTOPENIA DUE TO PERIPHERAL DESTRUCTION AND 
DECREASED PRODUCTION OF PLATELETS: 
 
 
Figure 8. ROC curve – IPF in patients with thrombocytopenia due to decreased 
production and peripheral destruction of platelets. 
 
An IPF of ³ 9.3% can distinguish thrombocytopenia due to peripheral destruction of 
platelets from hypoproductive thrombocytopenia with a sensitivity of 80% and a 
specificity of 71% (Figure 8). 
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Figure 9. Box plot highlighting the clear separation between the mean IPF values in 
patients with ethnic macrothrombocytopenia (G3) and in patients with peripheral 
platelet destruction (G1). 
 
 
 
Table 12. Minimum and maximum IPF values in the two patient groups from which 
the box plot was derived. 
Patient group Mean Minimum Maximum 
Peripheral destruction 18.9 1.9 44.8 
Macrothrombocytopenia 46.2 34.8 58.9 
 
An IPF of ³ 45% can distinguish between thrombocytopenia due to peripheral 
destruction of platelets from ethnic macrothrombocytopenia with 100% specificity 
and 66% sensitivity (Figure 9 and Table 12). 
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(E) PLATELET MORPHOLOGY IN THROMBOCYTOPENIA. 
Slides were prepared for all patients with thrombocytopenia and stained with modified 
Wright Giemsa stain (annexure for SOP) using the Beckman Coulter Automated 
Slidemaker and Stainer. These were reviewed and the platelets were categorized into 
three groups as shown in the table below (Table 13). 
Table 13. Morphological variation of platelets (size) in patients with 
thrombocytopenia due to decreased production and increased destruction of platelets 
(Median percentage and ranges). 
ETIOLOGY N 
 
SMALL 
PLATELETS 
LARGE 
PLATELETS 
GIANT 
PLATELETS 
DECREASED 
PRODUCTION  
81 
 
78% 
(30-100%) 
20% 
(0-70%) 
2% 
(0-20%) 
PERIPHERAL 
DESTRUCTION 
67 70% 
(10-100%) 
28% 
(0-82%) 
2% 
(0-20%) 
ETHNIC 12 41% 
(24-100%) 
57% 
(0-72%) 
2% 
(0-8%) 
Patients with peripheral destruction of platelets had a slightly higher percentage of 
larger platelets. Patients with ethnic macrothrombocytopenia seemed to have had a 
higher number of large platelets as compared to the other two groups. 
 
Table 14. Colour of platelet cytoplasm in Wright Giemsa stained slides. 
ETIOLOGY N GREY GREY 
BLUE 
BLUE NOT 
ASSESSED 
DECREASED PRODUCTION 87 21 58 2 6 
INCREASED DESTRUCTION 67 8 55 3 1 
ETHNIC 12 1 9 2 0 
Table 14 shows that more number of patients with peripheral destructive or ethnic 
macrothrombocytopenia had a higher number of platelets with a more bluish tinge to 
the cytoplasm. However, this finding was not statistically significant (p value = 0.06). 
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V. TRENDS OF IPF IN PATIENTS POST HSCT. 
During the study period, there were 24 patients with aplastic anaemia who underwent 
HSCT out of which 4 patients expired before achieving platelet engraftment. One 
patient did not have serial IPF measurements till date of engraftment. These 5 patients 
were excluded from the study. 2 patients were undergoing a second transplant after 
previous secondary graft failure. 18 patients with Beta Thalassemia major underwent 
HSCT during the study period but 7 patients were excluded as they did not have serial 
IPF measurements till date of engraftment. 7 patients with lymphoma underwent 
autologous HSCT during the study period out of which 3 patients were excluded (one 
patient expired before platelet engraftment and 2 patients did not have serial IPF 
measurements till date of engraftment).  Out of the 12 patients who underwent 
autologous HSCT for Multiple myeloma, 3 patients were excluded as they did not 
have serial IPF measurements till date of engraftment. 
 
 
      Figure 10. Total number of patients in different disease groups who underwent 
HSCT. 
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(A) PATIENT DEMOGRAPHICS, HLA CROSS MATCH STATUS AND 
CONDITIONING REGIMENS USED: 	
 
 
Figure 11. Age distribution of patients undergoing HSCT. 
                         
There was an almost equal number of children and adult patients in our study groups 
(Figure 11). The ages ranged from 2 years to 59 years. 
 
    
 
Figure 12. Gender distribution of patients undergoing HSCT. 
	
63% (27) of the patients were male and 16 patients were female (Figure 12). 
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Table 15. HLA (Human leukocyte antigen) match status of allogenic HSCT patients. 
HLA CROSS MATCH STATUS NUMBER OF PATIENTS 
Haplomatched 3 
Fully matched sibling donor 21 
Fully matched family donor 3 
Fully matched unrelated donor 1 
2 antigen mismatched sibling donor 1 
2 antigen mismatched unrelated donor 1 
Total 30 
 
 
 
21 out of 30 patients had a fully HLA cross matched sibling donor (Table 15).  
 
 
   Figure 13. Conditioning regimens used in patients undergoing 
 allogenic HSCT. 
60% of patients undergoing allogenic transplant had a non-myeloablative conditioning 
regimen (Figure 13). All patients with myeloma and lymphoma who underwent 
autologous HSCT were conditioned with Melphalan and BEAM protocol 
(Carmustine, Etoposide, Cytarabine and Melphalan) respectively. 
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(B) TRENDS OF IPF IN PATIENTS WITH APLASTIC ANAEMIA POST 
ALLOGENIC HSCT: 
 
Figure 14. Serial measurements of IPF in children with Aplastic anaemia post 
allogenic HSCT. Black circles indicate day of platelet recovery. Black line indicates 
upper limit of age specific reference interval for IPF (3.1%).  
 
 
Figure 15. Serial measurements of Immature platelet fraction (%) in adults with 
Aplastic anaemia post allogenic transplant. Black circles indicate day of platelet 
recovery. Black line indicates upper limit of age specific reference interval for IPF 
(6.1%).  
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IPF in patients with Aplastic Anaemia (Post Allogenic BMT): In this group of 
patients, serial measurements of IPF from Day 0 of transplant (i.e. day of infusion of 
peripheral blood stem cells) up until the day of platelet recovery and beyond have 
been represented in figures 14 and 15. On applying the upper limit of our reference 
interval for IPF as a cut off, 5 out of 7 adults and 8 out of 9 children went above the 
upper limit of reference intervals for the respective groups a median of 1 day and 1.5 
days before platelet recovery respectively. In total, this showed that in 81% of 
patients, IPF showed an early indication of impending increase in platelet count.  
 
	
 
 
Figure 16. Serial measurements of Immature platelet fraction (%) in children with 
Thalassemia post allogenic transplant (patients 1 - 5). Black circles indicate day of 
platelet recovery. Black line indicates upper limit of normal reference range for IPF in 
children (3.1 %). 
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Figure 17. Serial measurements of Immature platelet fraction (%) in children with 
Thalassemia post allogenic transplant (patients 6 - 11). Black circles indicate day of 
platelet recovery. Black circles indicate day of platelet recovery. Black line indicates 
upper limit of normal reference range for IPF in children (3.1 %). 
 
 
Figures 16 and 17 represent serial measurements of IPF from Day 0 of transplant (i.e. 
day of infusion of peripheral blood stem cells) up until the day of platelet recovery 
and beyond in patients with Thalassemia. By using the upper limit of our reference 
range for IPF in children as a cut off, i.e. 3.1%, we observed that the IPF values of all 
patients went above the reference range before the day of platelet recovery (median of 
3.5 days before recovery). 
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* PLT – Median platelet count. ** IPF – Median immature platelet fraction. 
Figure 18. Trends of Median IPF and Median platelet count over time in all adult 
patients post allogenic HSCT who engrafted (N=7). Black arrow indicates the median 
day of platelet recovery. Black line indicates age specific reference interval for IPF. 
	
Figure 18 shows that the IPF went above the age specific reference interval around 3 
days before the median day of platelet recovery. Beyond day 15, the graph shows a 
drop in the platelet count due to 2 patients who engrafted only after Day + 20 post-
transplant.   
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* PLT – Median platelet count. ** IPF – Median immature platelet fraction. 
Figure 19. Trends of Median IPF and Median platelet count over time in all children 
who engrafted post allogenic HSCT (N=22). Black arrow indicates the median day of 
platelet recovery. Black line indicates age specific reference interval for IPF. 
 
Figure 19 shows that the IPF went above the age specific reference interval around 3 
days before the median day of platelet recovery. Beyond day 15, the graph shows a 
drop in the platelet count due to 3 patients who engrafted only after Day + 20 post-
transplant.  
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* PLT – Median platelet count. ** IPF – Median immature platelet fraction. 
Figure 20. Trends of Median IPF and Median platelet count over time in all patients 
post autologous HSCT (N=13). Black arrow indicates the median day of platelet 
recovery. Black line indicates age specific reference interval for IPF. 
 
Figure 20 shows that the IPF went above the age specific reference interval around 3 
days before the median day of platelet recovery.  9 out of the 13 patients showed an 
increase in IPF above the upper limit of reference interval (>6.1%) a median of 3 days 
before the day of platelet recovery. 
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* PLT – Median platelet count. ** IPF – Median immature platelet fraction 
Figure 21.Trends of Median IPF and Median platelet count over time in patients with 
Multiple myeloma post autologous HSCT (N=9). Black arrow indicates the median 
day of platelet recovery. 
 
Figure 21 shows that the IPF started to show an increasing trend around 3 days before 
the day of platelet recovery.  7 out of the 9 patients showed an increase in IPF above 
the upper limit of reference interval (>6.1%) before the day of platelet recovery.  
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* PLT – Median platelet count. ** IPF – Median immature platelet fraction. 
Figure 22. Trends of Median IPF and Median platelet count over time in patients with 
Lymphoma post autologous HSCT (N=4). Black arrow indicates the median day of 
platelet recovery. 
 
Figure 22 shows that the IPF started to show an increasing trend around 3 days before 
the day of platelet recovery. 2 out of the 4 patients showed an increase in IPF above 
the upper limit of reference interval (>6.1%) before the day of platelet recovery. 
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Figure 23. Serial IPF measurements of 3 patients who underwent allogenic HSCT for 
aplastic anaemia and had primary engraftment failure. 
 
Figure 23 shows that there was a marked variation in IPF with no sustained rise seen 
in serial IPF values.  
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REFERENCE INTERVALS FOR PLATELET PARAMETERS 
Age specific reference intervals for the following parameters: MPV, IPF, PDW, P-
LCR and PCT from 248 healthy adults and 27 healthy children on both Sysmex XN 
9000 and Mindray BC 6800 platforms were determined. The data was tested for 
normality of distribution. Since none of these parameters had a normal distribution we 
used 5th and 95th percentiles as reference ranges. This lack of a normal distribution for 
platelet parameters has been reported previously and hence authors have used 
different methods for reference range calculation like Mean ± 2SD, 25th and 75th 
percentiles or minimum and maximum (98,99). Our reference interval of IPF in adults 
was 1.1 – 6.1% and 1.6 – 8.9% in the Sysmex and Mindray analysers respectively. 
The values we obtained for the Sysmex analyser were in keeping with the reference 
ranges obtained in studies by Briggs et al. and Seo et al. (59,100) but differ from those 
quoted in other studies like the one by Jung et al. which gives a lower cut-off of 3.2% 
as the upper limit of normal (99). This difference could be due to differences in the 
statistical tools used to derive the reference ranges.  
Our reference interval for IPF in children was much narrower and lower than that for 
adults and was taken as 0.4 – 3.1%. Seo et al. had reported a similar finding of an IPF 
nadir occurring between the ages of 2-6 years followed by increasing IPF to reach 
adult levels beyond 18 years of age (100). This phenomenon could be due to 
difference in platelet dynamics in children or could also be due to the smaller sample 
size that we had for the reference range calculation in children.  
It has been observed that individuals from North Eastern states of India, Bangladesh 
and Nepal have a high incidence of a phenomenon called constitutional ethnic  
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macrothrombocytopenia which is an asymptomatic condition wherein, the individual 
has giant platelets in the peripheral blood and thrombocytopenia (101). It has also 
been documented that these individuals have a high IPF (Median 25.5%) (102). Since 
our institution has a significant proportion of its patient population coming from these 
states, we calculated reference ranges separately for IPF from 131 healthy individuals 
from North Eastern India. We obtained a median IPF of 10.4% and a reference 
interval of 2.1 – 34.8% (5th and 95th percentile).  
 
AGREEMENT BETWEEN THE TWO ANALYSERS 
Bland Altman agreement statistics performed between the two analysers showed that 
majority of the data points fell within the 95% confidence intervals. The Intra-class 
correlation coefficient was found to be 0.92 (95% CI: 0.81-0.97) which suggested that 
there was a good agreement between the two analysers. There have been no previous 
studies that have looked at the agreement between these two analysers. 
 
STABILITY OF PLATELET PARAMENTERS ON BOTH ANALYSERS 
Previous literature so far has given contradicting evidence on stability of platelet 
parameters on Sysmex analysers. Studies by Briggs et al. on Sysmex XE series had 
shown that IPF was stable up to 48 hours of storage (59). However, certain other 
studies have quoted much lesser stability times varying between 3 – 24 hours with 
decreasing stability on storage at refrigerated conditions (62,63,83). The Sysmex XN 
analyser has been reported to have better stability of up to 48 hours with storage at 
room temperature or refrigerated conditions (27,80). The stability of these parameters  
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on Mindray BC6800 has not been studied so far. In our study, we found that IPF on 
Sysmex XN was stable up to 48 hours when stored at either room or refrigerated 
temperatures which was in keeping with previous studies. However, IPF on Mindray 
was stable only up to 8 hours on storage at room temperature and up to 4 hours on 
storage in refrigerated conditions beyond which there was a statistically significant 
rising trend in IPF values. MPV was equally unstable in both analysers with 
increasing values being obtained beyond 4 hours of storage at refrigerated 
temperatures. Platelet counts were stable up to 48 hours in both analysers. This lack of 
stability in IPF on Mindray could be due to the different fluorescent dye and effect of 
analytic reagents and methods in the chamber that is used in this analyser.  
 
CHARACTERISATION OF IPF IN THROMBOCYTOPENIA 
One of the objectives of the study was to study IPF in different patient groups, 
primarily to see if this parameter was different in patients who had a peripheral 
platelet destruction over those that had a bone marrow production problem. We also 
hypothesized that the trends of IPF during bone marrow recovery in patients who had 
undergone stem cell transplant for various hematological conditions could help to 
predict those who would display platelet recovery.  
 
Patient demographics: There was an even distribution of patients coming from all 
parts of the country. However, the local population accounted for only 25% of the 
total patient number. 45% of our patient population was from Bangladesh, Nepal and  
	 77	
eastern states of India like West Bengal, Jharkhand, Bihar, Orissa, Tripura, Meghalaya 
and Assam.  
71% of patients were adults with an age range of 4 months to 72 years. Mean age at 
presentation with thrombocytopenia was 32 years. 
There was an almost equal distribution of thrombocytopenia among men (52%) and 
women (48%), showing a slight male predominance.   
 
Etiologies of thrombocytopenia: The most common cause of thrombocytopenia in 
patients presenting to our institution during the study period was a decreased 
production of platelets from the marrow i.e. a hypoproductive cause of 
thrombocytopenia (44%, 87 out of 198 patients). This hypoproduction of platelets was 
due to a variety of conditions, the most common of which was aplastic anaemia (54%, 
47 patients) and marrow infiltrative pathologies like leukemia, lymphoma and 
myeloma (32%, 28 patients). The remaining 14% of patients had Myelodysplastic 
syndrome or Myeloproliferative neoplasms.  
 
Thrombocytopenia due to a peripheral destruction of platelets was seen in 34% of 
patients. Of this, immune thrombocytopenic purpura (ITP) was the most common 
cause (70%, 30 out of 67 patients). In the remaining 30% of patients, the peripheral 
platelet destruction was due to sequestration in an enlarged spleen. This finding is in 
agreement with the global data that ITP is the commonest cause of isolated 
thrombocytopenia (11).  
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About a quarter of patients (42 out of 198 patients, 22%) had thrombocytopenia due to 
causes which did not clearly fit into an isolated problem of platelet production or 
platelet destruction. Of these, the common causes were constitutional ethnic 
macrothrombocytopenia (28%) and megaloblastic anaemia (14%).  Other causes 
encountered included Paroxysmal nocturnal hemoglobinuria, Wiskott-Aldrich 
syndrome, chronic kidney disease, infections, MDS and MPN (with adequate bone 
marrow megakaryocytes), Bernard Soulier syndrome, Osteopetrosis and drug induced. 
We could not find any data on the common causes of thrombocytopenia with or 
without other cytopenias in the Indian population or others, in literature. 
 
PLATELET PARAMETERS IN PATIENTS WITH THROMBOCYTOPENIA 
Hypoproductive thrombocytopenia: Median impedance platelet counts in patients with 
a hypoproductive cause of thrombocytopenia was 16000/µl (IQR: 9000/µl – 
36000/µl). Median fluorescent platelet count (PLT-F) and manual smear platelet count 
was also similar being 15000/µl and 11250/µl respectively. The median IPF in this 
group was 6.6% (IQR: 4.6% – 10.1%) . When we excluded the 39 patients coming 
from North East India from this group, the median IPF dropped to 5.5% (IQR: 4% - 
8.2%). This drop in IPF was probably due to the high incidence of ethnic 
macrothrombocytopenia in the excluded group of patients which would have caused 
higher IPF values in them despite their hypoproductive bone marrow state. The 
median IPF values in this group was significantly higher than the median IPF of  our 
normal control population (Median: 2.5%). This is probably due to the marrow trying 
to compensate for the thrombocytopenia by producing platelets at a rate which is  
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higher than that seen in normal individuals in whom there is no stimulus for platelet 
production in the resting state. Patients with thrombocytopenia due to decreased 
platelet production (ex: aplastic anaemia, leukaemia, lymphoma involving marrow 
etc.) have lesser number of megakaryocytes within the marrow (103). So it is possible 
that even if these remaining megakaryocytes produced platelets at an accelerated rate 
to compensate for the thrombocytopenia, it will not match the rate of platelet 
production from a marrow with adequate megakaryocytes which is being stimulated to 
produce platelets due to a peripheral platelet consumption. Kickler et al. (68) had 
similar values of IPF in hypoproductive thrombocytopenia (Mean: 4.1%, Range: 0.8% 
- 8.8%) with the mean IPF being higher in patients with hypoproductive 
thrombocytopenia when compared to normal control population.  Abe et al. also 
obtained similar values of IPF in patients with aplastic anaemia (Mean: 6.4%, Range: 
2.8% - 10%) (66). Briggs et al. and Adly et al. also reported that patients with 
hypoproductive thrombocytopenia have significantly higher IPF values than the 
control population (59,67). 
The mean MPV, PDW and P-LCR in this group was 10.4 fL (± 2 SD: 4.8 – 16 fL), 
13.4fL (± 2 SD: 9.6 – 17.2 fL) and 36% (± 2 SD: 17.8 – 54.2%) respectively. The 
median PCT was 0.03% (IQR: 0.02 – 0.06%). These values differed slightly from that 
obtained Kaito et al. who had reported mean values of MPV, PDW and P-LCR in 
patients with aplastic anaemia as 10.2 fL, 11.6 fL and 25.7% respectively and from 
that obtained by Adley et al. who had mean values of 10.5 fL, 9.7 fL and 27.6% in 
patients with haematological malignancies. These differences were probably due to 
difference in analyser used (Sysmex XE series in the quoted studies) and differences  
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in the patients groups with hypoproductive thrombocytopenia studied. The median 
values for PCT in these patients were significantly lower than the normal controls. 
The MPV and PDW values were also lower though not significantly so. On the other 
hand, they had a significantly higher P-LCR than the control population. 
 
Thrombocytopenia due to peripheral destruction of platelets: Median impedance 
platelet counts in patients with a peripheral destructive cause of thrombocytopenia 
was 30000/µl (IQR: 12000/µl – 56000/µl). Median PLT-F count and smear platelet 
count was also similar being 34000/µl and 24750/µl respectively. We also found that 
PLT-F count was similar to PLT-I count when the platelet histograms were normal. 
When the histogram was abnormal (reflecting the presence of large platelets, 
numerous small platelets or significant platelet anisocytosis) the PLT-F and PLT-I 
counts started to differ from each other. The median IPF in this group was 15.5% 
(IQR: 9.9% – 27.8%) with a range of 1.9 - 44.8% . Kickler et al. obtained a mean IPF 
of 12.8% (Range: 2.3 – 35.4%), Briggs et al. reported a mean IPF of 16.8% (Range: 
2.3 – 52.1%), Adly et al. had a median IPF of 11.8% (Range: 2.8 – 39.8%) and Abe et 
al. reported a mean IPF of 17.4% (Range: 1.2 – 53.2%) (59,66–68). Even though the 
mean / median IPF and the maximum possible IPF that was recorded was not exactly 
the same, they were all universally above the upper limit of the normal reference 
ranges for IPF as was the case in our study as well. The median IPF in this group 
(15.5%) was also significantly higher than that of the control population (2.5%). 
The mean MPV, PDW and P-LCR in this group was 9.7 fL (± 2 SD: 5.9 – 13.5 fL), 
16.1 fL (± 2 SD: 10.1 – 22.1 fL) and 44.6% (± 2 SD: 26 – 63.2%) respectively. The  
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median PCT was 0.03% (IQR: 0.02 – 0.06%). Kaito et al. and Adly et al. reported 
higher mean values of MPV of 12.2 fL and 11.6 fL respectively in patients with ITP. 
However, mean values of  PDW and P-LCR obtained by Kaito et al. were similar to 
the values that we obtained i.e. 16.8 fL and 42.2% respectively (67,97). Adly et al. 
reported lower mean values of PDW and P-LCR i.e. 14.5 fL and 42.8% respectively 
and a higher mean value for PCT (0.1%) when compared to our study (67). These 
minor differences in values could be due to difference in analyser used (Sysmex XE 
series in the quoted studies) and the fact that all the quoted studies included only 
patients with ITP in their study groups whereas our study had included patients with 
hypersplenism as well.  
In our study, the mean MPV (9.7fL) and PCT (0.03%) in this patient group was 
significantly lower than the median MPV (10.7fL) and PCT (0.05%) values of the 
normal population. However, the mean PDW and P-LCR were significantly higher 
than that of the control population. These findings suggest that patients with 
thrombocytopenia due to a peripheral destruction of platelets have more larger sized 
platelets in circulation and a greater degree of platelet anisocytosis than normal 
individuals.  
 
Constitutional ethnic macrothrombocytopenia: Median impedance platelet counts in 
patients with ethnic thrombocytopenia was 47500/µl (IQR: 45000/µl – 56000/µl). 
Median PLT-F count and smear platelet count was higher being 67500/µl and 
66000/µl respectively, which was statistically significant. This difference was 
probably due to PLT-I count missing out on the large platelets due to their 
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misclassification as red blood cells by the analyser. The median IPF in this group was 
47.6% (IQR: 38.9% – 49.8%) which was significantly higher than the normal control 
population. The mean MPV was 10.5 fL (2SD: 5.6 - 15.5 fL) which did not differ 
significantly from that of the normal controls. PDW, PCT and P-LCR were not 
provided by the analyser because of abnormal platelet histograms in these patients due 
to the presence of giant platelets. Bhat et al. reported a lower median IPF of 25.5% 
(Range: 8 - 47.1%) in 77 patients with ethnic macrothrombocytopenia from West 
Bengal. This difference was probably because the population they included in their 
study also included patients with less severe thrombocytopenia (>100000/µl and < 
150000/µl) as well. When they categorised their patients based on different platelet 
count cut offs,  they obtained higher IPF values (30% - 35%) for platelet counts 
<100000/µl which is more similar to the value obtained by us. They also reported that 
Sysmex XN analyser failed to give an MPV, PDW, PCT and P-LCR in majority of 
these cases due to an abnormal platelet histogram (102).  
 
UTILITY OF PLATELET PARAMETERS TO DISTINGUISH BETWEEN 
CAUSES OF THROMBOCYTOPENIA 
Hypoproductive and peripheral destructive causes of thrombocytopenia: 
In our study, we found that platelet counts (PLT-I, PLT-F and smear platelet counts) 
were significantly lower in patients with hypoproductive thrombocytopenia. Of the 
platelet parameters studied, IPF, PCT, PDW and P-LCR were all significantly lower 
in these patients as well. The MPV values did not show any significant difference 
between the two groups. The median IPF in hypoproductive thrombocytopenia was  
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6.6% as compared to 15.5% in thrombocytopenia due to peripheral platelet 
destruction. We found that an IPF cut off of ³	9.3% can distinguish between these two 
groups with a sensitivity of 80% and a specificity of 71%.  
Our findings were similar to other studies carried out in this area. Abe et al. concluded 
that IPF was significantly higher in ITP when compared to patients with aplastic 
anaemia, MDS, leukemia and lymphomas. They suggested an IPF cut off of 7.7% to 
distinguish ITP from hypo-productive causes of thrombocytopenia with a sensitivity 
of 88% and specificity of 85.7%. However they also reported that MPV was also 
significantly higher in patients with ITP (66). Adley et al. observed that IPF was 
significantly higher in patients with ITP when compared to patients with a 
hematological malignancy. They suggested an IPF cut off of 9.4%, which could pick 
out patients with ITP with a sensitivity of 86.8% and specificity of 92.6%. They also 
found that IPF was significantly higher in patients with chronic ITP than in patients 
with acute ITP. However, our study did not show any statistical significance between 
these two sub groups, though the IPF was higher in patients with chronic ITP (Median 
IPF in acute ITP was 16.3% as compared to 22.4% in chronic ITP, p value - 0.12). 
The lack of statistical significance was probably because of the small patient numbers 
involved. This study also reported that PDW and P-LCR were significantly higher in 
patients with thrombocytopenia due to a peripheral destruction of platelets but that 
PCT was significantly lower in this group of patients when compared to patients with 
hypo-productive thrombocytopenia (67). This differed from our study since we had 
found that PCT was also significantly higher in patients with peripheral destruction of 
platelets. Kickler et al. also concluded that IPF was significantly higher in patients  
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with platelet destruction and that an IPF of > 9% was 100% specific for patients with 
peripheral platelet destruction (68).  Strauss et al., Koike et al. and Pons et al. also 
reported higher IPF values in patients with ITP than in patients with aplastic anaemia 
which was statistically significant (69–71).  Kaito et al. also reported significantly 
higher values of MPV, PDW and P-LCR in patients with ITP than in patients with 
aplastic anaemia (97). The lack of a significant difference in MPV between the two 
groups in our study could be due to differences in the analyser used and due to 
differences in the different types of diagnoses included under our broad patient 
groups.  
 
Peripheral destructive causes of thrombocytopenia and ethnic 
macrothrombocytopenia: 
These were the two groups of patients in our study who had higher platelet indices 
among patients with thrombocytopenia in our study. In clinical practice diagnostic 
difficulties exist when a patient from North Eastern India presents with 
thrombocytopenia as both ITP and ethnic macrothrombocytopenia can be 
asymptomatic (104,105). From our study, we found that platelet counts (PLT-I, PLT-F 
and smear platelet count) and IPF were all significantly higher in patients with ethnic 
macrothrombocytopenia than in patients with thrombocytopenia due to peripheral 
destruction of platelets. The median PLT-F count in patients with ethnic 
macrothrombocytopenia was 67500/µl as compared to 34000/µl in patients with ITP 
and hypersplenism. The median IPF in patients with ethnic macrothrombocytopenia 
was 47.6% as compared to 15.5% in patients with ITP and hypersplenism. Since there  
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was a clear separation between the median IPF values in patients with ethnic 
macrothrombocytopenia and in patients with peripheral platelet destruction, we came 
to the conclusion that an IPF of ³ 45% could distinguish between these two groups 
with 100% specificity. Ours is the first study to draw such a conclusion. A similar 
observation was made by Miyazake et al. who reported that the IPF was significantly 
higher in patients with MYH-9 related giant platelet disorders (Mean - 48.6%) than in 
patients with ITP (Mean - 18.4%).  
PCT, PDW and P-LCR could not be analysed as they were not provided by the 
analyser in patients with ethnic macrothrombocytopenia due to lack of generation of a 
platelet histogram from which these parameters are derived. This phenomenon has 
been reported previously in a study by Bhat et al. as well (102). 
 
RELATIONSHIP OF IPF WITH ADEQUACY OF BONE MARROW 
MEGAKARYOCYTES 
To see whether IPF truly does reflect megakaryocytic activity within the bone 
marrow, we correlated IPF levels independent of patient diagnoses with the presence 
or absence of megakaryocytes within the bone marrow. We found that the median IPF 
in patients with adequate or increased bone marrow megakaryocytes was 14.1% 
which was significantly higher than the median IPF of patients with decreased or 
dysplastic megakaryocytes (Median -  8.3%). No other studies have compared IPF 
with the adequacy of bone marrow megakaryocytes. This finding further gives 
evidence to the currently accepted concept of IPF being a good indicator of bone 
marrow thrombopoietic activity. 
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 PLATELET MORPHOLOGY IN PATIENTS WITH THROMBOCYTOPENIA 
The size of platelets and colour of platelet cytoplasm were assessed on stained 
peripheral smears of all 198 patients with thrombocytopenia. We found that 30% of 
circulating platelets in patients with thrombocytopenia due to a peripheral destructive 
cause were large and very large platelets in comparison to 22% in patients with a 
decreased production of platelets. In sharp contrast, 59% of circulating platelets in 
patients with ethnic macrothrombocytopenia were large and very large platelets. 
These findings do not correlate with our lack of significance in the MPV data between 
these groups. This is probably due to the fact that in most of our patients, the MPV 
was obtained from a fitted platelet histogram curve provided on the Beckman Coulter 
DXH 800 (since Sysmex XN did not provide an MPV in many of these cases) which 
may not be a true reflection of circulating platelet size. Ingram et al. were among the 
first to describe large platelets in circulation following acute blood loss, initially 
demonstrated in dogs (106). Ziegler et al. also reported that patients with immune 
thrombocytopenia had larger circulating platelets (9). Noris et al. reported that mean 
platelet diameter (obtained by a software algorithm) was significantly higher in 
patients with MYH9 mutation associated thrombocytopenia than in patients with 
immune thrombocytopenia (95). This finding is similar to the much higher number of 
large platelets seen in our population with ethnic macrothrombocytopenia. 
In 2011, a new stage in platelet maturation called pre-platelet (prePLT) was 
discovered which ranges in size from 2 to 10 µm and are anucleate.  PrePLT numbers 
were found to be high in rats following acute blood loss. It has been demonstrated that 
one prePLT can divide to form 2 normal sized platelets.  They are being equated to  
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young newly released platelets as well as the large platelets seen in inherited 
macrothrombocytopenia (4,107). Our finding of the presence of more larger sized 
platelets in patients with thrombocytopenia due to peripheral platelet destruction and 
more so in patients with ethnic macrothrombocytopenia could be explained by this 
phenomenon of prePLT release into the circulation by megakaryocytes due to 
accelerated platelet turnover or some platelet cytoskeletal abnormality (in ethnic 
macrothrombocytopenia subgroup) in these patients. 
Our assessment of platelet cytoplasmic colour showed that 87% of patients with a 
peripheral destructive cause of thrombocytopenia had more bluish tinged (more 
basophilic) platelets in circulation. The remaining 13% of platelets were only weakly 
basophilic with a more greyish appearance to the cytoplasm which is the normal 
cytoplasmic colour of platelets (7). 69% of patients with thrombocytopenia due to 
decreased platelet production, had more bluish platelets in circulation and 24% of 
them had predominantly greyish platelets. The difference in cytoplasmic colour was 
much more evident in patients with ethnic macrothrombocytopenia, 92% of whom 
had more basophilic circulating platelets. However, this difference in cytoplasmic 
colour between the three different cohorts was not statistically significant. 
Cytoplasmic colouration which is a function of staining and cytoplasmic content, 
varies from cell to cell based on the pH of the cytoplasm. The modified Wright-
Giemsa stain used in our study is a Romanowsky stain which has a basic dye which 
gives acidic substances a bluish colour and an acidic dye which gives basic substances 
a reddish or orange colour. Nucleic acids like RNA and DNA are acidic substances 
and hence take up the basic dye thus imparting a basophilic colour to any cell  
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structure that contains them. So a cytoplasm which is rich in RNA will be more bluish 
in colour (7). We know that newly released platelets in circulation have more RNA 
within their cytoplasm which could either be due to their larger size or due to their 
younger age (as RNA is lost with passage of time) or a combination of these two 
factors. Hence it can be hypothesized that these immature platelets when seen on a 
Romanowsky dye stained peripheral smear will have a more bluish tinge to the 
cytoplasm than the normally present circulating mature platelets. This hypothesis is 
supported by our findings in the assessment of platelet cytoplasmic colour. Since 
patients with peripheral destruction of platelets have a normally functioning bone 
marrow, they are able to compensate for the thrombocytopenia by producing platelets 
more effectively which is not so in patients with a hypoproductive cause of 
thrombocytopenia where the marrow response is blunted. This is probably why the 
former group had more bluish platelets in circulation.  
Patients with ethnic macrothrombocytopenia have very large platelets as evidenced by 
our morphological study of platelet size. It is possible that these large platelets have 
more RNA within their cytoplasm simply because of their large size or due to some 
alteration from normal in their production from megakaryocytes which is yet to be 
elucidated. This could be the reason behind our finding that the majority of these 
individuals had very basophilic platelets. This theory is also supported by our finding 
that patients with ethnic macrothrombocytopenia had the highest IPF values among all 
the patients in our study since IPF is a function of platelet size as well as platelet 
cytoplasmic RNA content.  There have not been any studies so far which have studied 
platelet cytoplasmic colour in correlation with IPF or aetiology of thrombocytopenia. 
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TRENDS OF IPF IN PATIENTS POST HEMATOPOIETIC STEM CELL 
TRANSPLANT 
Since IPF appears to be an indicator that has potential to predict the state of the bone 
marrow, we have attempted to utilize it as a marker of platelet recovery in different 
groups of patients who have undergone allogenic and autologous bone marrow stem 
cell transplantation for different haematological conditions specified below. 
 
Patient demographics: We followed up a total of 43 patients who underwent 
hematopoietic stem cell transplantation (HSCT). There were an almost equal number 
of children (51%) and adults in our study group and the ages ranged from 2 years to 
59 years. There was a slight male predominance with 63% of patients being males and 
only 37% females.  
 
Disease subgroups: Out of the 43 patients, 19 patients had aplastic anaemia, 11 
patients had beta thalassemia major, 9 patients had multiple myeloma and 4 patients 
had lymphoma (2 patients with Hodgkin lymphoma, 1 patient with Diffuse large B 
cell lymphoma and 1 patient with Angioimmunoblastic T cell lymphoma). 2 of these 
patients were undergoing a second transplant after a previous engraftment failure. The 
patients with Aplastic anaemia and Thalassemia underwent Allogenic HSCT (30 
patients) and the patients with Myeloma and Lymphoma (13 patients) underwent 
Autologous HSCT. 
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HLA cross match status and Conditioning regimens used: 21 out of 30 patients who 
underwent Allogenic HSCT had a fully HLA cross matched sibling donor transplant. 
3 patients had a fully matched family donor, 1 patient had a fully matched unrelated 
donor, 3 patients had a haplomatched donor and 2 patients had 2 antigen mismatched 
donors. 60% of patients who underwent Allogenic HSCT had a non-myeloablative 
conditioning regimen and the remaining 40% of patients had a myeloablative 
conditioning regimen. All patients with myeloma and lymphoma who underwent 
autologous HSCT were conditioned with Melphalan and BEAM protocol 
(Carmustine, Etoposide, Cytarabine and Melphalan) respectively. 
 
TREND OF IPF IN PATIENTS WITH APLASTIC ANAEMIA AND 
THALSSEMIA POST ALLOGENIC HSCT 
We followed up these patients with serial measurements of IPF from Day 0 of 
transplant (i.e. day of infusion of peripheral blood stem cells) up until the day of 
platelet recovery (which we defined as the third day of an unsupported platelet count 
of >20000/µl) and beyond. The median day of platelet recovery in patients with 
Aplastic anaemia was 12 days and that for patients with Thalassemia was 13 days. 
Aplastic anaemia: On applying the upper limit of our reference interval for IPF as a 
cut off, in 5 out of 7 adult patients and 8 out of 9 children, IPF went above the upper 
limit of reference intervals for the respective groups either a few days before or on the 
day of platelet recovery. In children, the IPF went above the reference range of 3.1% a 
median of 1.5 days before platelet recovery. In adults, the IPF went above the 
reference range of 6.1% a median of 1 day before platelet recovery.  In children the 
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interval by which the IPF preceded platelet recovery was found to range from 0 days 
(i.e. on the day of platelet recovery) to 16 days and in adults, this ranged from on the 
day of platelet recovery to 12 days before recovery. 
In total, this showed that in 56% of patients who engrafted, IPF showed an early 
indication of impending increase in platelet count. In 25% of patients, IPF went above 
reference interval on the day of platelet recovery. 2 patients did not show an increase 
in IPF above the reference interval even though they engrafted and in one patient, the 
IPF was always above the normal reference interval, probably because this patient was 
from Jharkhand and had an added component of constitutional 
macrothrombocytopenia contributing to the high IPF values.  
Thalassemia: All patients in this subgroup were children and we found that the IPF 
values of all patients went above the reference range (3.1%)  a median of 3.5 days 
(ranging from 0 to 12 days) before platelet recovery. 
Morkis et al. reported that IPF values of >6.2% predicted platelet engraftment within 
a few days in 92% of patients who underwent autologous and allogenic HSCT. The 
cut off of 6.2% was chosen because it was the upper limit of normal reference interval 
for the parameter. However, their criteria for platelet engraftment was different from 
ours in that they had taken the ''first of three days with an unsupported platelet count 
of  > 20000/µl'' as the day of platelet engraftment. They also observed that IPF 
showed a lot of variations when serially followed up in patients post allogenic HSCT 
(77).  
Goncalo et al.  recorded serial IPF in 46 adults who underwent allogenic HSCT and 
observed that there was a rise in IPF > 7% a median of 2 days before platelet 
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recovery. They had taken platelet recovery as the ''first of seven days with an 
unsupported platelet count of  > 20000/µl'' (78). Takami et al.  in 6 patients post 
allogenic HSCT reported that an IPF rise > 3% occurs one day before platelet 
engraftment which they defined as ''platelet count of > 30000/µl for 3 consecutive 
measurements on different days in the absence of platelet transfusions for at least 7 
days" (79). Briggs et al. in a study on 7 patients post allogenic HSCT concluded that 
there was a rise in IPF around 1-3 days before platelet recovery (no definite definition 
for this was provided) and that there were variations in IPF during the course of 
follow up. They attributed this variation to platelet transfusions stating that IPF values 
fell for 24 hours after a platelet transfusion. They had suggested that this could be due 
to a suppression of thrombopoiesis due to the transfusion (82). However, in our study, 
we did not find any consistent change in IPF values after platelet transfusions.  
Yamaoka et al. using a platelet recovery definition as "a platelet count  > 100000/µl 
for 3 consecutive days without platelet transfusions" concluded that patients post 
allogenic transplant (11 patients) with a peak IPF > 10% achieved platelet recovery a 
median of 2 days later (83).   
 
TREND OF IPF IN PATIENTS WITH MULTIPLE MYELOMA AND 
LYMPHOMA POST AUTOLOGOUS HSCT 
We followed up these patients with serial measurements of IPF from Day 0 of 
transplant (i.e. day of infusion of peripheral blood stem cells) up until the day of 
platelet recovery (which we defined as the third day of an unsupported platelet count 
of >20000/µl) and beyond. Most of these patients had IPF values being recorded only 
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every alternate day as we did not want to interfere with the follow up protocols that 
are in place at our institution. The median day of platelet recovery in patients with 
Multiple myeloma was 12 days and that for patients with Lymphoma was 15 days.  
Since all these patients were adults, we applied a cut off of 6.1% and found that the 
IPF in 9 out of the 13 patients studied (69% of patients) went above this value a 
median of 3 days before platelet recovery (ranged from 0 - 10 days). 2 patients did not 
show an increase in IPF above the reference interval even though they engrafted and 
in a further 2 patients, the IPF was always above the normal reference interval, 
probably because these patients were from North East Indian states and had an added 
component of constitutional macrothrombocytopenia contributing to the high IPF 
values.  
Van der Linden et al. in their study on 16 patients undergoing autologous transplant, 
defined platelet recovery as "an increase in platelets greater than its reference change 
value and not due to platelet transfusion" and concluded that an IPF cut off of 5.3% 
could predict platelet recovery within 2 days. They also did not find any consistent 
relationship between platelet transfusion and change in IPF levels (80).  Briggs et al.  
in a study on 8 autologous transplant patients concluded that there was a mean rise in 
IPF of 12.8% which preceded platelet recovery (not defined) by 1 to 2 days (82). 
 
From the above discussion, it is clear that a rise in IPF precedes platelet recovery by 1 
- 3 days in patients post allogenic or autologous HSCT. Our study also supports this 
view. The fact that different authors have used different definitions for platelet 
recovery and different cut-offs for IPF rise is probably the reason why we are not left 
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with a definite IPF cut off or a definite predictive time interval after IPF rise within 
which we can expect to see platelet recovery. Our study also supports the observations  
made by a few authors on the high variability of IPF in patients undergoing allogenic 
HSCT. This has been attributed to transient rises in IPF seen due to sepsis which is 
common in this patient group due to profound immunosuppression (82). Another 
reason why there is a difference in the number of days from rise in IPF to platelet 
recovery could be the fact that all these studies included a variety of patient groups 
(including patients with hematological malignancies and myelodysplastic syndrome) 
undergoing allogenic transplant and was not just limited to Aplastic anaemia and 
Thalassemia patients as was the case in our study. The bone marrow kinetics is 
different in different disease processes and hence may also influence recovery in 
different ways in the post-transplant period.  
 
TREND OF IPF IN PATIENTS WITH PRIMARY ENGRAFTMENT FAILURE 
Primary engraftment failure was defined as ''lack of absolute neutrophil count to reach 
³ 0.5 x 10⁹/L'' (108). We had 3 patients with aplastic anaemia who underwent 
allogenic HSCT in our study who were diagnosed with primary graft failure. One 
patient was an adult and the other 2 were children. When we looked at the serial IPF 
values in these patients, we found that the IPF value never went > 6.1% in the adult 
patient. In the two children, IPF did go > 3.1%, but only on day 22-23 which was 
much later than all the other engrafted patients. Another trend that we noticed was that 
there was no consistent rise in IPF values and that there were large variations in the 
daily IPF being recorded. This finding is probably because the marrow is unable to 
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produce platelets due to lack of donor cell engraftment. This is the first time that the 
trend of IPF is being looked at in patients with primary engraftment failure and we 
could not find any literature to compare our findings with.  
 
In conclusion, from our analysis of 43 patients who underwent allogenic and 
autologous HSCT, we found that the IPF went above the age specific reference 
interval cut offs in 33 patients (76%) and that this rise preceded platelet recovery by a 
median of 1 - 3.5 days. This time to platelet recovery differed based on the disease 
condition that the patient had being shortest in patients with aplastic anaemia post 
allogenic HSCT and longest in patients with thalassemia post allogenic HSCT. This 
could be explained by the co-existent hypersplenism that 7 out of 11 patients in our 
study had and the possibility that all the platelets that are being produced in the 
marrow are being sequestered in the spleen leading to a longer time to platelet 
recovery.  We were unable to provide a definite cut-off for IPF which could predict 
platelet engraftment due to the low patient numbers involved in the study and due to 
the marked day to day variation in IPF in these patients. Hence, we took the upper 
limit of the normal reference interval as our reference point. There is a wide variation 
in the IPF cut offs and definitions of platelet recovery that have been used from study 
to study and this is what has led to different results. In patients with primary 
engraftment failure, we found that there were marked daily variations in IPF and that 
there was never a sustained rising trend of IPF in these patients as was seen in others. 
Also, in 1 of these patients IPF never went above age specific reference interval limit.  
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With these findings, we are able to say that IPF (> 3.1% in children and > 6.1% in 
adults) can probably be used as a marker to predict platelet recovery in patients post 
HSCT and that serial monitoring of IPF with its trend analysis could also be a 
predictor of primary engraftment failure.  
 
From our analysis of 196 patients with thrombocytopenia, we found that the IPF in 
patients with a hypoproductive or peripheral destructive cause of thrombocytopenia is 
significantly higher than that of the normal control population. We also found that 
patients with thrombocytopenia due to peripheral platelet destruction have a 
significantly higher IPF than patients with decreased platelet production and that an 
IPF of ³ 9.3% can distinguish between patients with thrombocytopenia due to 
peripheral destruction of platelets from patients with thrombocytopenia due to 
decreased production of platelets with a sensitivity of 80% and a specificity of 71%. 
In addition, an IPF of ³ 45% can distinguish between thrombocytopenia due to 
peripheral destruction of platelets from ethnic macrothrombocytopenia with 100% 
specificity. Individuals with ethnic macrothrombocytopenia had the highest IPF 
values amongst all the patient groups studied. Interestingly, these individuals also had 
the highest proportion of large platelets with blue cytoplasm found on peripheral 
smear examination. Another noteworthy finding was that the IPF was significantly 
higher in patients with adequate and increased bone marrow megakaryocytes when 
compared to patients with decreased and absent bone marrow megakaryocytes. This 
could be evidence to support the current understanding of IPF as a marker of 
thrombopoietic activity of the bone marrow. 
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LIMITATIONS OF THE STUDY 
• Reference range calculation for the Indian population had to be done after 
excluding individuals coming from North East Indian states because of the high 
incidence of constitutional macrothrombocytopenia and resultant high values 
of IPF.  
 
• As it was a prospective study, the number of patients that could be enrolled for 
follow up after hematopoietic stem cell transplant was limited by the duration 
of the study period. Derivation of an absolute value of IPF or a percentage rise 
in IPF from baseline which would predict platelet recovery needs a larger 
cohort of patients and a more varied group of primary disease conditions so 
that we can observe differences if any, in patterns of IPF depending on the 
reason for HSCT. 
 
• We did not interfere with existing platelet transfusion protocols for patients 
post HSCT, and hence were unable to test whether our proposed time intervals 
from IPF rise till platelet recovery held true even without platelet transfusion 
support.  
 
• We had an interesting observation in the trend of IPF in patients with primary 
engraftment failure which has not been reported previously before, but further 
confirmation of this finding requires the follow up of more such patients. 
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CONCLUSIONS 
• Patients with thrombocytopenia due to peripheral platelet destruction have a 
significantly higher IPF than patients with thrombocytopenia due to decreased 
platelet production. 
 
• A subgroup of individuals from the North Eastern states of India have an 
asymptomatic form of thrombocytopenia called ethnic macrothrombocytopenia 
characterized by the presence of large blue platelets in peripheral smear and the 
highest IPF among the patient groups studied.  
 
• An IPF of ³ 9.3% can distinguish between patients with thrombocytopenia due 
to peripheral destruction of platelets from patients with thrombocytopenia due 
to decreased production of platelets with a sensitivity of 80% and a specificity 
of 71%. 
 
• An IPF of ³ 45% can distinguish between thrombocytopenia due to peripheral 
destruction of platelets from ethnic macrothrombocytopenia with 100% 
specificity. 
 
• IPF was significantly higher in patients with adequate and increased bone 
marrow megakaryocytes when compared to patients with decreased and absent 
bone marrow megakaryocytes. 
	 99	
• In majority of patients (76%) being followed up post HSCT, IPF went above the 
age specific reference interval cut offs and this rise preceded platelet recovery 
by a median of 1 - 3.5 days. 
 
• The time to platelet recovery after rise in IPF differed based on the disease 
condition that the patient had and the type of transplant (autologous or allogenic) 
being shortest in patients with aplastic anaemia post allogenic HSCT and longest 
in patients with thalassemia post allogenic HSCT and in patients post autologous 
stem cell transplant. 
 
• Patients with primary engraftment failure had a marked daily variation in IPF 
levels with no sustained rise in IPF and in one out of the three patients studied, 
the IPF did not go above the age specific reference interval cut off. 
 
With these findings, we conclude that IPF may be a reliable marker of 
thrombopoietic activity within the marrow and that it can be used as marker to 
distinguish between thrombocytopenia due to peripheral platelet destruction from 
thrombocytopenia due to decreased platelet production and ethnic 
macrothrombocytopenia. It may also have potential utility in the monitoring of 
patients post hematopoietic stem cell transplantation to predict platelet recovery and 
thereby curb unnecessary platelet transfusions in these patients. From our study we 
also find that analyzing the pattern of IPF could be even used to predict primary 
engraftment failure in this patient group. 
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ANNEXURE 1 
IRB APPROVAL LETTER 
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ANNEXURE 2 
STUDY PROTOCOL 
 
I. IPF in thrombocytopenia due to decreased production or peripheral destruction of 
platelets:                                                                   
 
 
 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
             
Patients diagnosed with Aplastic anaemia, Fanconi anaemia, 
Myelodysplastic syndrome and Idiopathic Thrombocytopenic 
purpura from Hematology OPD and patients diagnosed with 
Chronic liver disease with portal hypertension from 
Blood sample collected from 
them prior to initiation of 
treatment. 
Smears made to study  
platelet morphology 
Initially run on Beckman 
Coulter (DXH 800) cell counter 
to get platelet counts. 
Run through Sysmex XN9000 to 
derive IPF% 
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II. Trends of IPF in patients post hematopoietic stem cell transplantation: 
 
 
 
 
 
Patients posted for hematopoietic stem cell transplantation. 
Patients with aplastic anaemia planned on treatment with Anti thymocyte globulin. 
Patients with Acute myeloid leukemia planned on chemotherapy. 
First sample collected prior to initiation of treatment and run on Beckman Coulter 
(DXH 800) and Sysmex XN9000. 
Hematopoietic stem cell 
transplant: 
Serial IPF% and platelet 
count measurements on day 
3, day 5, day 7 and day 10 
and day 21 of treatment on 
Sysmex XN9000. 
	
	
AML on chemotherapy: 
Serial IPF% and platelet 
count measurements on 
day 10, day 14, day 21 
and day 28 of treatment 
on Sysmex XN9000. 
 
Aplastic anaemia on 
ATG: 
Serial IPF% and platelet 
count measurements in 
week 2, week 4, week 6, 
week 8, week 10 and 
week 12 of treatment on 
Sysmex XN9000. 
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ANNEXURE 3 
 
DATA COLLECTION FORMS 
 
 
IPF Study in Patients with Regenerating Bone Marrow 
 
Study 
Number 
 CATEGORY AA CHEMO BMT 
Hospital 
Number 
 Name  Age   
Ward  Gender   
Category APLASTIC 
ON ATG 
      
 Day 0 Week 2 Week 4 Week 6 Week8 Week 10 Week 12 
Plt_1        
Plt_2        
IPF%        
Category CHEMO       
 D0 D10 D14 D21 D28   
Plt_1        
Plt_2        
IPF%        
        
Category BMT       
 
D0 D1 D2 D3 D4 D5 
Till day 
of 
recovery 
Plt_1        
Plt_2        
IPF%        
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Standard Data Collation form for Thrombocytopenic patients and controls  
	
S. 
No 
Hospital 
Number 
 
Diagnosis PLT-I PLT-F IPF PDW PCT P-LCR Megakary
ocyte 
Adequacy 
1          
2          
3          
4          
5          
 
 
S. 
No 
Hospital 
Number 
 
Diagnosis PLT-S Platelet size Platelet cytoplasm Total 
platelets 
assessed 
1    Small Large Very 
large 
Grey Bluish 
grey 
Blue  
2           
3           
4           
5           
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ANNEXURE 4 
STANDARD OPERATING PROTOCOL FOR UniCel DxH 800 SLIDE MAKER 
AND STAINER  
2.0 Procedure to use UniCel DxH 800 Slide Maker and Stainer.  
2.1 Purpose: To increase workflow efficiency and provide excellent smears every time and 
eventually increase the laboratories productivity.  
2.2 Principle: The HaemaSphere technology captures the blood adherence to the aspiration 
tubing which provides a more reliable and consistent smear regardless of blood consistency.  
2.3 Performance specification  
140 slides/hour 
2.4 Primary sample: K2EDTA blood  
2.5 Type of container: Lavender top vacutainer.  
2.6 Sample and equipment requirement  
1. Slide maker 
a. 1 mL blood.  b. Sample holding cassette.c. Beckman Coulter DxH 800 Slides d. Printer 
ribbon.e. Smear holding basket.  
2. Stainera. Modified Wrights stain.  b. Modified Wright Giemsa stain. c. Wright stain 
bufferd. Distilled water.  
2.7 Procedure  
2. Open the slide ejector door and load the slides with the painted side up and the frosted side 
to the right side.  
3. Close the slide ejector door.  
4. Manually scan and fill in all the reagents and stains.  
5. Ensure the communication status is glowing green (online).  
6. Select the option make slide and stain on the “Detail status”.  
7. Load the blood sample into the cassette provided by the company.  
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8. Then select/ check the processing mode whether it be the Primary or the secondary mode. 
Cassette is transfer to the barcode station where the barcodes are read and the cassettes are 
transferred to the left or right mixing stations where the samples are mixed by sixteen 
inversions. The primary mode is the fully automated mode where the analyser transports 
the sample and does the mixing and aspirates 100µl all of sample and processes it.  
9. The Secondary mode or the emergency mode is used only to process emergency/STAT 
samples and samples with a low volume. On this mode the analyser stops a previous 
analysis and immediately smears the sample that has been fed.  
10. Care should be taken that the bar coded samples are placed in a manner that they can be 
scanned by the analysers scanning system.  
10. The clean spreader slide head on 22degree angle used. The slide is pushed from the smear    
shuttle into printer shuttle. the painted side print the barcode and transfer to the basket 
elevator for drying. 
  
11. After the smear dries the robot arm picks the basket and sends it to the stainer where the 
slides get stained and dry. 
 
12. After the smears get stained the robot arm takes the basket and puts them into the I/O 
drawer position. 
 
Protocol options (DxH Slide maker and Stainer Default)  
Bath Supply type Percentage  Duration 
1  Modified Wright stain  100%  1 minute  
2  Modified Wright Giemsa stain  100%  2 minutes  
3  Stain/Buffer  Wright Giemsa 30%, Wright stain 
buffer 70%  
6 minutes  
4  Distilled H2O  100%  1min 30 
sec  
5  
  
Distilled H2O  100%  
  
2 minutes  
  
Drying duration 3 minutes  
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ANNEXURE 5 
 
STANDARD OPERATING PROTOCOL FOR ENUMERATING PLATELETS 
ON A STAINED PERIPHERAL SMEAR 
 
Estimation of Number of platelets: 
It is very important to give an accurate estimation of the number of platelets as 
well as the description of the morphology. The abnormal platelets should describe such as 
giant or bizarre, platelet estimate can usually be made by each platelet in the average oil 
immersion field representing 15,000 platelets per mm3. It is important to remember that these 
estimates are only reliable when the blood has been drawn in EDTA and slides are prepared 
within an hour. This estimate should not be used when the smear has been made from a 
finger prick. 
 
Platelets markedly decreased - 0 – 50,000/mm3 
Platelets moderately decreased - 51,000 – 1,00,000/mm3 
Platelets slightly adequate - 1,00,000 – 3,00,000/mm3 
Platelets slightly increased - 3,00,000 – 5,00,000/mm3 
Platelets moderately increased - 5,00,000 – 6,60,000/mm3 
Platelets markedly increased - More than 6,50,000/mm3 
 
QC procedures: 
Duplicate checking 
 
9.10 Calibration: NA 
 
9.11 Interference: NA 
 
9.12 Results: NA 
 
9.13 Range of testing: Semi quantitative 
 
9.14 Alert values: NA 
 
9.15 Potential source of variation: NA 
 
9.16 References: 
1. Handbook of Medical Laboratory Technology, Second edition, Robert H Carman, 91- 
95.
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